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91 INTRODUCTION
Atherosclerosis is a major cause of morbidity and mortality all over the world,
and its most common manifestation is coronary artery disease (CAD). The
pathology of atherosclerosis is due to deposition of lipids, especially
cholesterol, in the arterial wall intimal layer both intracellularly and
extracellularly. Cholesterol in the atherosclerotic plaques is mainly derived
from circulating lipoproteins, especially low density lipoprotein (LDL), and high
levels of LDL cholesterol in blood are strongly associated with CAD (Keys
1970, Martin et al 1986). Furthermore, increased atherogenicity is associated
with small dense LDL particles (Austin et al 1988, Griffin et al 1994) and
minimally modified LDL generated by various physical and chemical
modifications (Steinberg et al 1989).
Sialic acids are aminosaccharides characteristically located in the terminal
ends of carbohydrate chains of glycoproteins, and their removal exposes
galactose molecules that can interact with receptors, which leads to the
removal of the proteins from the circulation (Stryer 1988). LDL has sialic acid
-containg carbohydrate chains both in its protein and lipid parts
(Swaminathan and Aladjem 1976). Because of the role sialic acid has in the
metabolism of glycoproteins its content in LDL is an interesting factor with
regard to the atherogenicity of this lipoprotein. Desialylation of LDL has been
shown to increase its uptake into cultured cells (Filipovic et al 1979, Orekhov
et al 1992) and its interaction with extracellular matrix components (Camejo
et al 1985) proportionately to the degree of desialylation. In addition, a low
sialic acid content has been found in LDL of CAD patients as compared with
healthy control subjects (Orekhov et al 1991b, Ruelland et al 1993), although
all studies do not agree on this (Chappey et al 1998). Consequently,
desialylation of LDL seems to take place in vivo, and thus it could be an
atherogenic modification of the lipoprotein.
The level of LDL cholesterol in blood is regulated by the metabolism of
cholesterol and LDL. As the sialic acid content of LDL affects its catabolism
at the cellular level, it could be assumed that the content is also associated
with LDL metabolism in vivo. This work was conducted to investigate the
relations of LDL sialic acid content with various factors connected with
atherosclerosis, including the concentration, composition, and metabolism of
lipids and lipoproteins, and with states where the risk of CAD is elevated,
namely type 2 diabetes mellitus (DM) and type II hyperlipidemias. In addition,
the effect of statin treatment on LDL sialic acid content was studied.
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2 REVIEW OF THE LITERATURE
2.1 Overview of lipoprotein metabolism
In human plasma, lipids are transported as lipoproteins which consist of
cholesterol esters and triglycerides in the hydrophobic core, and of free
cholesterol, phospholipids and apolipoproteins on the hydrophilic surface.
Plasma lipoproteins are separated into five major classes on the basis of their
density: chylomicrons (d < 0.94 g/ml), very low density lipoproteins (VLDL,
d = 0.94-1.006 g/ml), intermediate density lipoproteins (IDL, d = 1.006-1.019
g/ml), low density lipoproteins (LDL, d = 1.019-1.063 g/ml), and high density
lipoproteins (HDL, d = 1.063-1.210 g/ml) (Havel and Kane 1995). The main
features of lipoprotein metabolism are presented in Figure 1.
Chylomicrons are very large lipoproteins that consist mainly of triglycerides
and of minor amounts of cholesterol and phospholipids. Their major protein is
apolipoprotein (apo) B-48, and they also contain apolipoproteins A, C and E.
Chylomicrons are formed postprandially from dietary fats in the intestinal
epithelial cells, and they enter the circulation via lymph. In the blood,
triglycerides are rapidly hydrolyzed into free fatty acids by lipoprotein lipase.
Some cholesterol and phospholipids, and the A and C apolipoproteins are
transferred to HDL. The resulting particle, called a chylomicron remnant, is
taken up by hepatic receptors.
VLDL is produced in hepatocytes, and consists of a large amount of
triglycerides and smaller amounts of cholesterol and phospholipids. Its major
protein is apo B-100, and it contains also some E and C apolipoproteins.
VLDL carries endogenously synthesized lipids from the liver. In the blood,
lipoprotein lipase hydrolyzes triglycerides, and the size of the particles
diminishes. Some of these particles, called VLDL remnants, are directly
removed from the blood by LDL receptors on hepatocytes. VLDL surface
remnants, especially phospholipids, are transported to HDL via the function
of phospholipid transfer protein (PLTP) (Jiang et al 1999). The remaining
particles are transformed into IDL, and, through loss of apolipoproteins E and
C and further hydrolysis of triglycerides by hepatic lipase, further into LDL.
LDL consists of one single copy of apo B-100, and of large amounts of
cholesterol esters and smaller amounts of free cholesterol, triglycerides and
phospholipids. LDL is the main carrier of cholesterol in blood, and it is
responsible for transporting cholesterol to peripheral cells. Apo B interacts
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Figure 1. Overview of lipoprotein metabolism. Forward cholesterol transport, cholesterol
transport from the liver to peripheral cells. Reverse cholesterol transport, cholesterol transport
from peripheral cells back to the liver for excretion. See text for explanation.
A-I, apo A-I; B, apo B-100; B-48, apo B-48; C, apo Cs; CE, cholesterol ester; CETP,
cholesterol ester transfer protein; CM, chylomicron; CMR, chylomicron remnant; E, apo E; HL,
hepatic lipase; LPL, lipoprotein lipase; TG, triglycerides. α-HDL and preβ-HDL, HDL particles
displaying α- and preβ-mobilities.
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with specific LDL receptors located on cell surfaces in many tissues, including
the liver, and thus LDL particles are mainly removed from the circulation.
HDL is formed as a precursor in cells of the liver and intestine. Nascent HDL
contains mainly protein and phospholipids, but in the circulation it gains
material, including phospholipids and free cholesterol via lipolysis of
triglyceride-rich particles and from cell membranes. The primary
apolipoproteins in mature HDL are apo A-I, A-II and A-IV. Free cholesterol in
HDL is esterified by lecithin:cholesterol acyltransferase (LCAT), and
cholesterol esters are transferred from HDL to apo B -containing lipoproteins
by cholesterol ester transfer protein (CETP) in exchange for triglycerides (Tall
1986). Thus, HDL has an important role in reverse cholesterol transport: first
specific HDL subclasses (preβ-HDL) function as primary cholesterol
acceptors and are able to remove cholesterol from peripheral cells, and after
cholesterol esterification cholesterol esters are delivered from HDL to apo B
-containing lipoproteins, which can be removed from the circulation by
hepatic receptors.
A sixth lipoprotein class, lipoprotein(a) (Lp(a)), consists of one LDL particle
associated with one molecule of a glycoprotein called apo(a) (Utermann
1989, Utermann 1995). Its density range is 1.04-1.125 g/ml, overlapping
those of LDL and HDL. Apo(a) is secreted by the liver but the site of
assembly and that of catabolism of Lp(a) are unclear. Its plasma
concentration is genetically determined and there are large interindividual
differences. A physiological role for Lp(a) has not been found, but apo(a) has
a close structural resemblance with plasminogen, and it has been shown to
be able to interfere with fibrinolysis (Utermann 1995).
2.2 Low density lipoproteins
2.2.1 LDL particle structure
Like all mature lipoproteins, LDL is a spherical particle. It has a density of
1.019-1.063 g/ml and a diameter of 22-28 nm. It contains 35-45% of
cholesterol esters and 6-12% of triglycerides in the core, and 20-25% of
phospholipids, 6-10% of free cholesterol, and 20-25% of protein on the
surface (Deckelbaum 1987). The sole protein of LDL is apo B, and one LDL
particle always contains one molecule of apo B.
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2.2.2 LDL metabolism
LDL is the end product of VLDL metabolism (Sigurdsson et al 1975, Reardon
et al 1978, Fisher et al 1980, Thompson et al 1987, Demant et al 1996). It is
produced from small VLDL particles, larger VLDL particles being rapidly
removed from the circulation (Packard et al 1984). The production rate
depends both on the rate at which VLDL is produced and the rate at which
VLDL remnants and IDL are removed from the circulation via LDL receptors,
and also on the lipolytic activity in the transformation of VLDL and IDL into
LDL. In addition, some LDL can be directly secreted by hepatocytes,
especially in hyperlipidemic states (Janus et al 1980, Kissebah et al 1984,
Fisher et al 1994, Gaw et al 1995), but also in normolipidemia (Cohn et al
1990).
LDL is cleared from the circulation mainly by the specific LDL receptor (Brown
and Goldstein 1976, Shireman et al 1977, Brown and Goldstein 1986,
Goldstein et al 1995), the rest being removed by unspecific pathways, for
example by the scavenger receptor pathway. The LDL receptor is located on
the surface of hepatocytes and peripheral cells, and it interacts with LDL via
apo B. After the binding of LDL to the receptor, the receptor-lipoprotein
complex is endocytosed and LDL dissociates from the receptor. The
synthesis of LDL receptors in the cell is suppressed by cholesterol derived
from LDL, which phenomenon regulates the amount of cholesterol entering
the cell (Brown et al 1981, Goldstein et al 1995).
Serum level of LDL is dependent both on the LDL production rate and LDL’s
clearance from the circulation (Grundy et al 1985, Kesäniemi et al 1987). LDL
cholesterol level has been reported to have both a positive correlation with
the production of LDL apo B and a negative correlation with the clearance of
LDL from the circulation in some studies (International Collaborative Study
Group 1986, Miettinen et al 1992, Gylling et al 1994), while others have
reported the level to be associated only with LDL production (Kesäniemi and
Grundy 1982, Vega et al 1985). The activity of LDL receptors affects the rate
of clearance of LDL from the circulation but also its production rate, because
VLDL remnants are taken up from the circulation by the same receptors, and
when their activity is low, more VLDL is transformed into LDL.
Serum levels of LDL cholesterol usually increase with age, and both the
catabolism (Kesäniemi et al 1987) and the production (Gylling et al 1994) of
LDL is lower in elderly men. Women seem to have a slightly faster catabolism
of LDL apo B than men, and estrogen therapy raises LDL catabolic rate
(Kesäniemi et al 1987). In type 2 DM, LDL cholesterol levels are regulated by
the catabolism but not the production of LDL apo B (Gylling and Miettinen
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1996a, Gylling and Miettinen 1997), and compared to non-diabetics the
production of LDL is normal but its catabolism is low (Howard et al 1987),
possibly resulting from glucosylation of LDL (Howard 1987, Kesäniemi et al
1987).
High serum levels of LDL cholesterol, i.e. hypercholesterolemia or type IIa
hyperlipidemia, can be a result of elevated LDL production, low LDL
clearance, or both. Familial hypercholesterolemia (FH) is a condition caused
by a defect in the gene encoding the LDL receptor (Goldstein et al 1995).
Heterozygotes have about half the normal receptor activity, and homozygotes
have practically no functional LDL receptors. Defective clearance during the
whole length of the lipolytic pathway (VLDL → IDL → LDL) leads to high
levels of LDL cholesterol in the blood (Shepherd and Packard 1989);
heterozygotes usually have two- to threefold higher LDL cholesterol levels
than normal population. A far more common form of hypercholesterolemia is
polygenic in origin and in this case the serum levels of LDL cholesterol are
mildly to moderately high.
High levels of LDL cholesterol can be associated with high serum triglyceride
levels; this condition is called combined hyperlipidemia, or type IIb
hyperlipidemia. Familial combined hyperlipidemia (FCHL) is a genetically
heterogenic entity, and affected individuals in a family may have either
hypercholesterolemia (type IIa), hypertriglyceridemia (type IV), or both (type
IIb) (Grundy et al 1987, Kane and Havel 1995). The basic defect in FCHL
appears to be overproduction of apo B (Kissebah et al 1984, Teng et al 1986,
Brunzell et al 1987, Ericsson et al 1992), and serum apo B levels are
characteristically elevated. Accordingly, it has been suggested that the
disorder should be called hyperapobetalipoproteinemia instead of FCHL
(Sniderman et al 1992). However, with the present diagnostic criteria there is
no simple method to discriminate between affected and unaffected
individuals in a family (Porkka et al 1997), but recent findings implicate that
the presence of FCHL can be genetically determined in the near future
(Pajukanta et al 1998, Pajukanta et al 1999). The catabolism of LDL in FCHL
is low to normal (Teng et al 1986, Ericsson et al 1992, Aguilar-Salinas et al
1997), but overall the kinetics of apo B are heterogenic (de Graaf and
Stalenhoef 1998).
2.2.3 LDL subclasses
Plasma LDL is not a homogeneous lipoprotein population, but consists of
multiple subclasses with differing size and density (Lindgren et al 1969, Shen
et al 1981, Krauss and Burke 1982). The density and molecular weight of
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LDL particles are negatively correlated so that as the density of the particles
increases, their weight and size decrease (Crouse et al 1985). LDL derived
from the VLDL-IDL lipolytic cascade is initially large and buoyant, and as a
result of exchange of lipids between lipoproteins it becomes smaller and
denser (Fisher et al 1980, Thompson et al 1987). Small dense LDL particles
consist of relatively more protein and less cholesterol than bigger and more
buoyant LDL particles (Teng et al 1983). Serum triglyceride levels are
positively related with LDL density so that hypertriglyceridemia is often
accompanied by small dense LDL particles (Nelson and Morris 1983, Crouse
et al 1985, Swinkels et al 1989b, Campos et al 1992a, Campos et al 1995,
Nikkilä et al 1996). Predominance of a small dense LDL subtype, LDL
subclass pattern B, is partially genetically determined; about 15% of
American population have an allele that leads to LDL subclass pattern B
(Austin and Krauss 1986). The subclass pattern is also affected by such
factors as age and gender (de Graaf et al 1992, Austin 1993). LDL subclass
pattern B is associated with high serum triglyceride and low HDL cholesterol
levels (McNamara et al 1987, Austin et al 1988).
2.2.4 LDL and atherosclerosis
High serum total cholesterol concentration has been strongly connected with
atherosclerosis in numerous studies (e.g. Keys 1970, Martin et al 1986,
Brunner et al 1987). Being the main carrier of cholesterol in blood, LDL is
also the principal lipoprotein causing atherosclerosis (Grundy 1995b). LDL
has been found in atherosclerotic plaques (Hoff et al 1979), and it has been
shown in vitro to be able to transform smooth muscle cells and macrophages
into foam-cells (Goldstein et al 1979, Brown and Goldstein 1983), the major
cells of atheromatous lesions. Vast epidemiological studies have attested a
strong independent association between LDL cholesterol levels and the risk
of atherosclerotic disease (e.g. the Framingham Study, Kannel et al 1979).
Furthermore, clinical trials of cholesterol-lowering treatments have led to a
marked fall in the incidence of cardiac events due to CAD and in mortality
from CAD (Lipid Research Clinics Program 1984, Frick et al 1987, Huttunen
et al 1988, Scandinavian Simvastatin Survival Study Group 1994, West of
Scotland Coronary Prevention Study Group 1995, Cholesterol and Recurrent
Events Trial Investigators 1996, AFCAPS/TexCAPS Research Group 1998,
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group 1998).
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2.2.4.1 Arterial proteoglycans
Camejo et al first documented that LDL forms complexes with a protein
present in aortic and coronary intima-media (Camejo et al 1975, Camejo et al
1980). Furthermore, the serum of subjects with acute myocardial infarction
(AMI) has been reported to form more of these insoluble complexes than the
serum of control subjects (Camejo et al 1976, Linden et al 1989). The
concentration of LDL and its structural properties affect its binding to arterial
proteoglycans (Camejo et al 1989). Small dense LDL has a higher affinity for
the proteoglycans (Bondjers et al 1990, Camejo et al 1991), and a
predominance of small dense LDL is associated with a higher rate of LDL-
proteoglycan complex formation (Anber et al 1996, Anber et al 1997).
Reversible association with arterial proteoglycans seems to cause changes in
LDL that render it atherogenic (Hurt and Camejo 1987, Ismail et al 1994), and
at least one of these changes is an increase in the susceptibility to oxidation
(Hurt-Camejo et al 1992). Arterial proteoglycans have also been reported to
increase the rate of proteolytic fusion of LDL particles taking place in the
arterial intima (Pentikäinen et al 1997). Part of the cellular uptake of LDL-
proteoglycan complexes has been shown to be mediated by an unspecific
scavenger pathway possibly not subject to regulation like the LDL receptor
pathway (Hurt et al 1990, Vijayagopal et al 1993). It has been suggested that
the retention of lipoproteins in the arterial wall by their binding to
proteoglycans causes lipoprotein deposition in arterial tissues (Bondjers et al
1990, Camejo et al 1991, Hurt-Camejo et al 1997, Camejo et al 1998).
Complex formation between LDL and arterial proteoglycans has been shown
to be strongly correlated with serum cholesterol, LDL cholesterol and apo B
concentrations and to diminish significantly during lipid-lowering medication
(Wiklund et al 1996).
2.2.4.2 Small dense LDL
An association between small dense LDL and CAD has been established in
many studies. CAD patients have been shown to have smaller and denser
LDL particles than controls (Crouse et al 1985, Swinkels et al 1989a, Tornvall
et al 1991, Campos et al 1992b, Coresh et al 1993, Tornvall et al 1993,
Griffin et al 1994, Gardner et al 1996), and an increased risk of AMI has been
connected with LDL subclass phenotype B (Austin et al 1988) and with small
LDL particle diameter (Stampfer et al 1996). However, in some studies the
association has not been so clear (Lahdenperä et al 1996, Sherrard et al
1996), but in all these studies a strong inverse relation between LDL particle
size and serum triglyceride level has been evident. Thus, the association
between small dense LDL and CAD may not be independent, but linked to
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other CAD risk factors. Small dense LDL is associated, besides with high
serum triglyceride levels, also with high LDL and low HDL cholesterol levels
(Austin et al 1990b, Campos et al 1992a, Krauss 1998).
Men, who are more prone to CAD than premenopausal women, have a
smaller LDL particle diameter than women of same age (McNamara et al
1987, Swinkels et al 1989b, Campos et al 1992a, Nikkilä et al 1996, Sherrard
et al 1996). After menopause the size of LDL particles shrinks in women as
the risk of CAD grows, indicating that female hormones have an effect on
LDL particle size (Campos et al 1988, Campos et al 1992a). Smoking and the
use of beta-blocking agents are associated with a relative rise in dense LDL
(Campos et al 1992b, Griffin et al 1994). Subjects with combined
hyperlipidemia (Austin et al 1990a, Dejager et al 1993, Hokanson et al 1995)
or hyperapobetalipoproteinemia (Kwiterovich 1988) have an increased
prevalence of small dense LDL phenotype. Type 2 DM patients, who have an
elevated risk of CAD (e.g. Kannel and McGee 1979, Uusitupa et al 1990,
Koskinen et al 1992), have smaller and denser LDL particles than non-
diabetics (Feingold et al 1992, Stewart et al 1993), and LDL subclass
phenotype B has been shown to be associated with an increased risk of type
2 DM (Austin et al 1995). Furthermore, also non-diabetic subjects with
glucose intolerance have a predominance of small dense LDL particles
(Suehiro et al 1995).
Oxidation of LDL renders it more atherogenic, and small dense LDL seems to
be more liable to oxidative modifications than larger LDL (de Graaf et al
1991, Tribble et al 1992, Chait et al 1993, de Graaf et al 1993). Jaakkola et al
(1993) documented that dense LDL subfractions increased intracellular
cholesterol concentration in cell culture, and this effect was significantly
stronger for the dense LDL of CAD patients than for that of controls.
Shrinking of LDL particle size seems to cause progressive changes in the
conformation of LDL apo B, thus possibly affecting its receptor affinity (Teng
et al 1985). However, Knight et al (1986) found no differences in the binding
and degradation of light and dense LDL in fibroblasts and macrophages.
They also reported that both subfractions used the LDL receptor pathway
and not the scavenger pathway (Knight et al 1986), while Thompson et al
(1987) documented similar binding and degradation of light and dense LDL
through both the LDL receptor and the scavenger receptor. On the contrary,
in two other studies small dense LDL had a weaker affinity for the LDL
receptor than larger LDL (Galeano et al 1994, Galeano et al 1998), and
higher affinity for LDL receptor independent binding sites (Galeano et al
1998). Therefore it could preferably be taken up via scavenger receptors on
macrophages of extrahepatic tissues, like artery walls, thus promoting the
formation of foam cells.
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2.2.4.3 Other risk factors of atherosclerosis
Low serum level of HDL cholesterol is a well documented CAD risk factor
(Nikkilä 1953, Miller and Miller 1975, Miller et al 1977, Castelli et al 1986,
Frick et al 1990, Lehto et al 1993). Serum triglyceride levels have also been
positively associated with CAD risk, especially in women (Nieminen et al
1992, Bengtsson et al 1993, Stensvold et al 1993), and high levels are often
linked with low HDL cholesterol concentration (Robinson et al 1987, Austin
1989) and LDL subclass pattern B (Krauss 1998).
Serum levels of Lp(a) have been widely reported to be higher in CAD patients
than in healthy controls (Genest et al 1991, Sandholzer et al 1992, Kario et al
1994, Bostom et al 1996), and thus Lp(a) has been suggested to be a CAD
risk factor (Utermann 1989, Loscalzo 1990, Stein and Rosenson 1997).
However, this association between CAD and Lp(a) has not been found in the
Finnish population (Jauhiainen et al 1991, Alfthan et al 1994). Another trial
failing to establish any value of serum Lp(a) for predicting the risk of AMI was
the Physicians’ Health Study (Ridker et al 1993). At present the interaction of
CAD and Lp(a) remains unconfirmed (Maher and Brown 1995, Jialal 1998). In
addition, Lp(a) seems to be partially dependent on other cardiovascular risk
factors (Labeur et al 1992). The mechanism of action of Lp(a) in
atherosclerosis is still not clear, but Lp(a) has been shown to be able to
interfere with various factors involved in thrombogenesis and thrombolysis
(Scanu 1992, Stein and Rosenson 1997).
2.3 Sialic acids
2.3.1 General
   CH2OH
  H     C    OH
  H     C     OH
 H O
H3C     C     N   COO-
   H
     O    H      H
 H   OH
   OH         H
Figure 2. N-acetyl neuraminic acid.
Sialic acids are small
aminosaccharides. They consist of
a neuraminic acid backbone with
one or multiple O- or N-linked side
chains, the most abundant
derivative in humans being N-
acetylneuraminic acid (Figure 2).
Sialic acids are numerous in many
human tissues and fluids (Warren
1959b, Huttunen 1966,
Sillanaukee et al 1999a). In serum,
sialic acids are mostly bound to the
carbohydrate chains of
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glycoproteins and glycolipids. Sialic acid residues are located in the terminal
ends of carbohydrate chains of many glycoproteins, for instance
immunoglobulins and peptide hormones, and when the terminal sialic acid is
removed by neuraminidase of the vascular endothelium, a galactose
molecule is revealed. Specific receptors on hepatocytes recognize these
asialoglyco-proteins and remove them from the circulation (Stryer 1988).
2.3.2 Serum sialic acid
A high serum total sialic acid (TSA) concentration has been associated with a
number of conditions (Sillanaukee et al 1999a). Many studies have
demonstrated a positive association between high TSA levels and the
incidence of CAD (Lindberg et al 1991, Watts et al 1995a, Råstam et al
1996). TSA seems to be linked with other CAD risk factors, namely high
serum cholesterol and triglyceride concentrations and low HDL cholesterol
concentration (Wakabayashi et al 1992, Wu et al 1999), high serum
concentration of apo B and smoking and physical inactivity (Lindberg et al
1993), and high serum Lp(a) levels (Kario et al 1994). TSA concentration has
been also shown to be higher in American than Japanese subjects even after
adjustment for other CAD risk factors, this being in accordance with the
higher prevalence of CAD in American population (Lindberg et al 1997).
However, other studies have not found any difference in TSA level between
angiographically separated CAD and non-CAD subjects (Salomone et al
1998, Wu et al 1999).
Serum TSA level has been shown to be elevated in DM (Crook et al 1993,
Crook et al 1996), and associated with CAD risk in diabetic subjects (Pickup
et al 1995). TSA is also an indicator of microalbuminuria in DM both in cross-
sectional (Crook et al 1994, Chen et al 1996) and follow-up studies
(Yokoyama et al 1996). Besides, TSA concentration is higher in women than
in men with DM, which could explain why DM increases the relative risk of
CAD more in women than in men (Pickup et al 1997). TSA level is also
elevated in many malignant diseases (Sillanaukee et al 1999a), during
pregnancy (Crook et al 1997a), and in alcohol abuse (Sillanaukee et al
1999b). It is also high in inflammation (Sillanaukee et al 1999a) and positively
correlated with erythrocyte sedimentation rate (Miettinen and Nikkilä 1960,
Crook et al 1997b) and serum concentration of C-reactive protein (Wu et al
1999). Accordingly, serum TSA level seems to be an unspecific but sensitive
marker of acute phase reactions, probably because of the pronounced
content of sialic acid in many acute phase proteins.
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2.3.3 Sialic acid in vascular tissue
Freshly infarcted myocardium has been shown to have a greater sialic acid
content than normal myocardium (Huttunen et al 1972). Both vascular
endothelium and red blood cells are rich in sialic acid and thus have a high
negative charge creating a repulsion between endothelium and blood cells,
which can inhibit blood clotting (Born and Palinski 1985). Treatment of cells
with neuraminidase that removes a major part of their surface sialic acids has
been shown to promote the uptake of LDL into the cells (Görög and Born
1982, Görög and Pearson 1984).
2.3.4 Sialic acid in lipoproteins
2.3.4.1 Chylomicrons, VLDL and IDL
The sialic acid content of chylomicrons has not been studied, while a few
researchers have investigated the sialic acid content of other triglyceride-rich
lipoproteins. An early study found the highest sialic acid content in VLDL,
whereas levels in IDL, LDL and HDL did not differ from each other (Fontaine
and Malmendier 1975). Similarly, two recent studies reported that the sialic
acid content decreased with increasing lipoprotein density from light VLDL to
dense IDL, then being similar until dense LDL (Anber et al 1997, Millar et al
1999). Another study described decreasing sialic acid content from VLDL to
LDL and further to HDL (Harada et al 1998). In these studies, the sialic acid
contents of the protein and lipid parts were not separated.
2.3.4.2 LDL
Glycoprotein. LDL has sialic acid residues both on its lipid and protein
parts. The largest part of the sialic acid has been reported to be in the protein
part of LDL, that is, in apo B (Tertov et al 1993). Apo B is a glycoprotein with
20 potential N-glycosylation sites, out of which up to 16 asparagine (Asn)
residues are glycosylated (Yang et al 1986, Taniguchi et al 1989). About 5-9
mass-% of apo B is carbohydrate, and there are two major types of
carbohydrate chains, one of which is neutral and the other acidic
(Swaminathan and Aladjem 1976, Taniguchi et al 1989). They consist of the
monosaccharides mannose, galactose, N-acetylglucosamine and sialic acid.
The structures of the two chains are shown in Figure 3. The acidic chain has
one or two terminal sialic acid residues followed by galactose molecules.
Sialic acid constitutes 10% of  the total  carbohydrate in apo B,  but unlike the
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     Sialic acid   Sialic acid
Man Man    Gal Gal
Man Man   GlcNAc    GlcNAc
Man    Man    Man     Man
  Man  Man
GlcNAc      GlcNAc
GlcNAc      GlcNAc
Figure 3. The two major carbohydrate
chains of LDL apo B. Both are N-linked
sugar chains and bound to 16 Asn
residues distributed along the apo B-100
polylpeptide chain. Gal = galactose;
GlcNAc = N-acetylglucosamine; Man =
mannose.
other monosaccharides, the
contents of which are fairly
constant, the amount of sialic acid
varies markedly between
individuals (Swaminathan and
Aladjem 1976). The apo B
molecule in LDL is calculated to
contain usually 12-14 sialic acid
residues per particle (Taniguchi et
al 1989). LDL apo B differs from
most serum glycoproteins by
having more galactose than sialic
acid residues (Taniguchi et al
1989), and the amount of
monosialylated oligosaccharides,
reflecting the number of free
galactose residues, can be
calculated to be on the average
four per LDL particle. A recent
study confirmed that all LDL
particles in plasma have free galactose residues at the ends of the
carbohydrate chains, indicating that LDL apo B is always partially desialylated
(Bartlett and Stanley 1998). The sialic acid content of LDL has a very strong
positive correlation with LDL apo B concentration (Fontaine and Malmendier
1978), attesting that a large part of the sialic acid in LDL is bound to apo B.
Glycolipids. Gangliosides are sialic acid -rich glycosphingolipids transported
in serum by lipoproteins, 66% of total serum gangliosides being transported
by LDL and smaller amounts by other lipoproteins, and thus they also
contribute to LDL sialic acid content (Dawson et al 1976, Senn et al 1989).
Gangliosides probably contain all the sialic acid associated with the lipid part
of LDL. In addition to the monosaccharides of LDL apo B, the lipid part of
LDL contains galactosamine and glucose but no mannose (Tertov et al
1993). Sialic acid constitutes 6-7% of the total carbohydrate in LDL lipid. The
content of galactose is markedly higher than that of sialic acid also in the lipid
part of LDL (Tertov et al 1993), thus contributing to the number of free
galactose residues in the lipoprotein particle.
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2.3.4.3 Cell culture studies
Many forms of modifications have been observed to increase the
atherogenicity of LDL (Steinberg et al 1989). Regarding the role of sialic acid
in the metabolism of glycoproteins, its content in LDL could affect the
atherogenicity of LDL. This has been studied in cell cultures. Incubation with
neuraminidase leading to desialylation of either aortic cells, LDL, or both,
caused a rise in aortic uptake of LDL (Day 1976). Furthermore, desialylation
of LDL was shown to double its binding and uptake into human fibroblasts
(Filipovic and Buddecke 1979), and there was a positive correlation between
the degree of desialylation and the enhancement of uptake (Filipovic et al
1979). In addition, a recent study described accelerated uptake of cholesterol
from desialylated LDL to macrophages (Harada et al 1998). Harada et al
(1998) also reported that desialylation of LDL increased the transport of
cholesterol esters from HDL to LDL by CETP, and desialylation of HDL
decreased its capacity to remove cholesterol from cells, both effects
promoting atherogenesis. However, two other studies found no difference in
the cellular binding and degradation of native and desialylated LDL (Attie et
al 1979, Shireman and Fisher 1979).
LDL with low sialic acid content formed insoluble complexes with arterial
proteoglycans avidly, and there was a significant negative correlation
between the sialic acid content of LDL and the relative avidity to form these
complexes (Camejo et al 1985). This finding was confirmed in a recent study,
where a fall in the sialic acid content of LDL raised its ability to interact with
arterial proteoglycans (Millar et al 1999). Since the arterial proteoglycans
have a strong electronegative charge (Camejo et al 1991) and desialylation
of LDL diminishes its negative charge, the increased affinity could partially be
due to reduced electronegative repulsion.
Enzymatic treatment of LDL with the combination of trypsin, cholesterol
esterase and neuraminidase turns LDL into non-homogeneous lipid particles
similar to those found in atherosclerotic lesions (Bhakdi et al 1995). This
modified LDL does not contain oxidized lipids but has a high negative charge.
It accumulates at a high rate into macrophages, this being mediated at least
partially by the scavenger receptor pathway, and induces immunological
reactions that promote early development of atherosclerotic lesions, such as
activation of the complement system, and chemotaxis, adhesion and
transendothelial migration of blood monocytes (Bhakdi et al 1995, Klouche et
al 1998, Klouche et al 1999). All these effects were stronger for the
enzymatically modified LDL than for acetylated or oxidized LDL, but were not
detectable in LDL treated with only one or two of the above-mentioned
enzymes.
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Apart from desialylation, another modification of LDL, acetylation, augments
its cellular uptake and degradation, and this is mediated not by LDL receptors
but by scavenger receptors (Goldstein et al 1979, Wiklund et al 1991). Such
receptors also seem to be involved in the catabolism of desialylated
glycoproteins, including LDL. Desialylated glycopeptides bind to a hepatic
lectin, the avidity of this binding being highly dependent on the number of
free terminal galactose residues, that is, on the degree of desialylation (Lee
et al 1983). Furthermore, a high density of galactose residues increases the
binding of asialo-orosomucoid both to a lectin receptor on hepatocytes, and
to an asialoglycoprotein receptor on macrophages (Ozaki et al 1995).
Assumably, desialylated LDL can also be taken up by these receptors.
Indeed, LDL and chylomicron remnants have been reported to be able to
bind to an asialoglycoprotein receptor on hepatocytes (Windler et al 1991),
and desialylation of chylomicrons increases their hepatic uptake and
degradation, probably due to interaction with this asialoglycoprotein receptor
(Guldur et al 1997). Moreover, LDL is documented to enter cells besides
through the LDL receptor pathway, also through a galactose-specific lectin
receptor pathway (Grewal et al 1996).
2.3.4.4 Coronary artery disease
Since the sialic acid content in LDL seems to be associated with
atherogenesis, it might have a role in CAD. A Russian group has carried out
extensive studies on the relations of LDL sialic acid content with
atherosclerosis and CAD. They first discovered that serum or LDL of CAD
patients caused a significant rise in cholesterol content of normal aortic cells
during incubation, while serum or LDL from healthy subjects did not change it
(Orekhov et al 1988, Tertov et al 1989a). Lipid and protein compositions of
these LDLs were similar, but the sialic acid content was markedly lower in
LDL of CAD patients (Orekhov et al 1989, Orekhov et al 1991b, Tertov et al
1992a, Tertov et al 1992b). Neuraminidase treatment of LDL from healthy
subjects made it atherogenic, and there was a strong negative correlation
between LDL sialic acid content and the amount of cholesterol accumulated
intracellularly (Orekhov et al 1989, Orekhov et al 1992, Tertov et al 1992a,
Tertov et al 1992b). In addition, LDL separated from normal aortic intima and
from fatty streaks had a lower sialic acid content than plasma LDL (Tertov et
al 1996a). These findings together support the hypothesis that desialylation is
an atherogenic LDL modification taking place in vivo (Sobenin et al 1991,
Orekhov et al 1992). During incubation, a decrease in the sialic acid content
was the first modification observed in LDL, followed by gain of atherogenicity
and decrease in the lipid content and size of the particles (Tertov et al 1998).
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Moreover, it has been proved that sialic acid is implicated in the antigenic
sites of LDL (Goldstein and Chapman 1981), and Orekhov et al (1991a)
found, compared with healthy controls, in sera of CAD patients a thirty-fold
greater amount of autoantibodies against LDL that had a strong affinity for
desialylated LDL. Circulating immune complexes from blood of CAD patients
were discovered to be atherogenic (Tertov et al 1990, Tertov et al 1996b),
and LDL from circulating immune complexes was sialic acid -poor (Tertov et
al 1996b). LDL was separated from both CAD patients and healthy subjects
to sialic acid -rich and sialic acid -poor fractions by affinity chromatography,
and it turned out that the proportion of desialylated LDL was considerably
higher in CAD patients than in controls (Tertov et al 1992b). Desialylated LDL
from both groups raised the intracellular lipid content, but this effect was
much stronger for desialylated LDL from CAD patients. Sialic acid -poor LDL
and LDL from CAD patients also formed aggregates during incubation while
sialylated LDL or LDL from healthy subjects did not (Tertov et al 1992b,
Tertov et al 1992c), and a strong positive correlation between LDL
aggregation and intracellular cholesterol accumulation was demonstrated
(Tertov et al 1989b, Tertov et al 1992c).
Other groups have come up with controversial results about differences in the
sialic acid content of LDL between CAD patients and controls. Ruelland et al
(1993) found lower a LDL sialic acid content in CAD patients than in
angiographically verified non-CAD subjects, but LDL sialic acid content was
not correlated with the severity of CAD. Furthermore, other studies with
asymptomatic hypercholesterolemic subjects revealed no differences in LDL
sialic acid content between subjects who in angiography were seen to have
either no atherosclerotic plaques or one or more plaques (Chappey et al
1995, Chappey et al 1998). These results imply that the sialic acid content of
LDL is not associated with the extent of CAD. In addition, LDL sialic acid
content was even slightly higher in subjects with both CAD and peripheral
atherosclerosis and in patients suffering from AMI than in those with CAD
only and in controls (Chappey et al 1998), while another research group
reported decreased LDL sialic acid content immediately after coronary artery
by-pass surgery (Jahangiri et al 1999). However, a recent study found lower
sialic acid content in both light and dense LDL of CAD patients compared
with healthy controls (Millar et al 1999).
LDL from DM patients also turned out to be poor in sialic acid and able to
cause intracellular cholesterol deposition, and as in CAD patients and
controls there was a strong negative correlation between the sialic acid
content of LDL and the degree of atherogenicity (Tertov et al 1992a, Sobenin
et al 1993, Sobenin et al 1994). A more recent study again found no
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difference in LDL sialic acid content between DM patients and control
subjects (Ruelland et al 1997).
Little is known about the importance of LDL sialic acid content in the
metabolism of LDL, but two studies have reported that a reduction of LDL
sialic acid content by neuraminidase treatment leads to faster LDL catabolism
(Hendrix et al 1975, Malmendier et al 1980).
Only a couple of studies have investigated LDL sialic acid content in
hyperlipidemia. Barbosa et al (1995) stated the sialic acid content of both
light and dense LDL to be high in combined hyperlipidemia but low in
hypercholesterolemia compared with normolipidemia. Another study showed
low LDL sialic acid content associated with hypercholesterolemia in DM
patients (Maruhama et al 1983).
Two studies have shown an inverse connection between LDL sialic acid
content and serum triglyceride levels (La Belle and Krauss 1990, Chappey et
al 1995), and a negative correlation with LDL cholesterol and positive with
HDL cholesterol level have also been documented (La Belle and Krauss
1990). However, Millar et al (1999) found no correlation between serum
cholesterol or triglyceride concentrations and LDL sialic acid content.
The sialic acid -containing gangliosides, transported in serum mainly by LDL,
have also been shown to be associated with atherosclerosis (Prokazova and
Bergelson 1994). Gangliosides stimulate LDL aggregation (Mikhailenko et al
1991), and LDL incubated with gangliosides is avidly taken up by
macrophages (Prokazova et al 1991) and fibroblasts (Filipovic et al 1981) but
poorly by hepatocytes (Prokazova et al 1986) thus probably interfering with
the clearance of LDL from the circulation to the liver. Furthermore, serum
ganglioside concentration is high in hypercholesterolemia proportionately to
the increase in cholesterol concentration (Dawson et al 1976, Senn et al
1992), and antibodies against gangliosides have been detected in serum of
CAD patients (Golovanova et al 1998). In addition, high amounts of
gangliosides have been found in atherosclerotic lesions compared to
unaffected intima (Breckenridge et al 1975, Mukhin et al 1989).
2.3.4.5 LDL density classes
Within the LDL density range, the sialic acid content falls with growing
particle density and diminishing size (La Belle and Krauss 1990, Millar et al
1999). Furthermore, Tertov et al demonstrated that desialylated LDL
separated from total LDL was smaller and denser than sialic acid -rich LDL,
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and poor in cholesterol and triglycerides (Tertov et al 1992b, Tertov et al
1996b). In addition, as the density of the particles rose, their sialic acid
content decreased and their ability to accumulate cholesterol into cells
increased (Tertov et al 1992b). In accordance with these results, La Belle and
Krauss (1990) also reported that subjects with LDL subclass pattern B had a
lower sialic acid content in LDL than those with subclass pattern A, and the
difference appeared to be in the glycolipid and not in the protein part of the
particle.
2.3.4.6 Oxidation and electronegativity
Tertov et al (1992b) found no differences in the content of oxidation products
in sialic acid -poor and sialic acid -rich LDL particles, and another study found
that the desialylation of LDL had no effect on its susceptibility to peroxidation
(Sattler et al 1991). However, in two other studies neuraminidase treatment
decreased the susceptibility of LDL to oxidation (Dousset et al 1994, Myara et
al 1995). A recent study reported that desialylation of LDL with
neuraminidase caused physical and chemical modifications in the structure of
apo B, which could account for its lowered susceptibility to oxidation (Dousset
et al 1998). Barbosa et al (1995) showed that the effect of desialylation on
LDL oxidizability was dependent on the density of LDL and on the type of
hyperlipidemia; light LDL was more resistant to oxidation in both type IIa and
IIb hyperlipidemia than in controls, but dense LDL of IIb hyperlipidemic
subjects was more susceptible to oxidation than that of normolipidemic
subjects, and its desialylation raised its resistance to oxidation, while it
decreased the resistance to oxidation of dense LDL in type IIa
hyperlipidemia. On the other hand, a fall in LDL sialic acid content during
peroxidation has also been reported (Tanaka et al 1997).
An electronegative subfraction of LDL was found to be sialic acid -poor and
atherogenic, and it was suggested that this electronegative subfraction could
be identical with the desialylated subfraction (Tertov et al 1995, Tertov et al
1996a). However, another group separated an electronegative LDL
subfraction with a high sialic acid content, and its proportion of total LDL was
positively correlated with LDL cholesterol concentration (Demuth et al 1996).
2.3.4.7 Lp(a)
Lp(a), which consists of LDL and apo(a), contains six times as much sialic
acid as LDL (Ehnholm et al 1972, Utermann 1989). Since its density range
overlaps that of LDL, it is possible that LDL separated by ultracentrifugation
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contains some Lp(a), this possibly affecting its sialic acid content in analysis.
However, the sialic acid content of LDL has been proved not to be correlated
with serum Lp(a) levels (Chappey et al 1995).
Lp(a) is more resistant to peroxidation than LDL (Sattler et al 1991,
Beaudeux et al 1996), but neuraminidase treatment was shown to either not
affect (Beaudeux et al 1996) or reduce (Sattler et al 1991) the resistance, the
latter result leading to the suggestion that the higher resistance of native
Lp(a) to peroxidation could be due to its higher sialic acid content as
compared with LDL. Like LDL, Lp(a) from CAD patients was reported to be
sialic acid -poor and atherogenic in cell culture compared with Lp(a) from
healthy controls; unlike native Lp(a) desialylated Lp(a) formed aggregates,
and their formation was strongly correlated with the extent of intracellular
cholesterol deposition (Tertov and Orekhov 1994).
2.4 Cholesterol metabolism
2.4.1 Cholesterol absorption
Cholesterol is derived to the body from two sources, diet and cellular
synthesis. Cholesterol elimination from the body is mediated by the liver,
which can transform cholesterol into bile acids. Both free cholesterol and bile
acids are secreted into bile. Dietary and biliary cholesterol is absorbed from
the small intestine into enterocytes, where it is incorporated into chylomicrons
and secreted into the circulation. Unabsorbed cholesterol and bile acids are
excreted from the body in feces as neutral steroids and bile acids. The
absorption of cholesterol from the intestine depends on the amount of
cholesterol in diet and in bile, and on the absorption efficiency of cholesterol,
which varies considerably interindividually, the usual range being 30 to 80 %
(Grundy 1983). Cholesterol absorption efficiency has been reported to
regulate serum cholesterol levels in Finnish men (Kesäniemi and Miettinen
1987), so that cholesterol absorption efficiency was correlated positively with
serum and LDL cholesterol levels (Kesäniemi and Miettinen 1987, Miettinen
and Kesäniemi 1989, Vanhanen and Miettinen 1995), and negatively with
cholesterol synthesis (Kesäniemi and Miettinen 1987, Gylling and Miettinen
1989, Miettinen and Kesäniemi 1989). However, another study reported no
correlation of cholesterol absorption with serum and LDL cholesterol levels
(Gylling and Miettinen 1988). Lowered cholesterol absorption efficiency has
been observed in many conditions, including obesity (Miettinen and
Kesäniemi 1989) and DM (Gylling and Miettinen 1997).
28
Small amounts of plant sterols are present in human serum, and the most
common of these are campesterol and sitosterol. They are totally of dietary
origin, and are absorbed in the small intestine similarly to cholesterol, but less
effectively. In serum, they are transported by lipoproteins and thus their
concentration is highly dependent on serum cholesterol concentration. The
ratios of campesterol and sitosterol to cholesterol are positively correlated
with cholesterol absorption efficiency (Tilvis and Miettinen 1986, Vuoristo et al
1988, Miettinen et al 1990), and the measurement of their concentrations
from serum represents a simple method for the estimation of cholesterol
absorption efficiency.
Cholestanol is a metabolite of cholesterol found in small amounts in blood,
and transported by lipoproteins. Its ratio to cholesterol is strongly correlated
with the ratios of campesterol and sitosterol (Miettinen et al 1998), and, like
these plant sterols, it is a reliable indicator of cholesterol absorption efficiency
(Miettinen et al 1989).
2.4.2 Cholesterol synthesis
Cholesterol synthesis takes place mainly in the liver, but nearly all human
cells are capable of synthesizing cholesterol. The initial step in cholesterol
synthesis is the conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) into mevalonic acid by HMG-CoA reductase, which is the rate limiting
enzyme in cholesterol synthesis. Mevalonic acid is then transformed into
squalene, and after many stages finally into cholesterol. Some of the
cholesterol precursor sterols that are part of the chain leading from squalene
to cholesterol are present in detectable amounts in serum, particularly
∆8-lathosterol, desmosterol and lathosterol (Miettinen 1968, Miettinen 1969).
They are transported in serum by lipoproteins similarly to cholesterol. The
ratios of these precursor sterols to cholesterol are correlated positively with
cholesterol synthesis rate (Björkhem et al 1987, Miettinen et al 1990), and
negatively with cholesterol absorption efficiency. Thus, the precursor sterol
ratios can be used as indicators of cholesterol synthesis rate.
Cholesterol synthesis in the body is strictly regulated (Brown and Goldstein
1986). Circulating lipoproteins, especially LDL, deliver cholesterol to
peripheral and liver cells, and enter the cells principally via the LDL receptor.
In cells, cholesterol esters are hydrolyzed to free cholesterol, which can be
used as a constituent of cell membranes, in the biosynthesis of steroid
hormones, or re-esterified for storage. Cholesterol entering the cell from LDL
suppresses the cell’s own cholesterol synthesis thus keeping up a
homeostasis in the cholesterol content of the cell. In hepatocytes, cholesterol
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can also be secreted back to the blood in lipoprotein particles or it can be
converted into bile acids or secreted as free cholesterol with bile acids to the
bile.
Cholesterol synthesis averages 9-13 mg/kg of body weight in humans per
day (Nestel et al 1969). It is high in obesity (Miettinen 1970),
hypertriglyceridemia (Briones et al 1986), and DM (Bennion and Grundy
1977, Briones et al 1986, Gylling and Miettinen 1997), and low in
hypercholesterolemia (Miettinen 1970, Miettinen 1971). In FH, low cholesterol
synthesis rate is associated with high CAD mortality (Miettinen and Gylling
1988). Both positive (Gylling and Miettinen 1989) and negative (Miettinen et
al 1992, Gylling and Miettinen 1997) correlations have been reported
between cholesterol synthesis rate and serum and LDL cholesterol
concentrations, but most studies (Gylling and Miettinen 1988, Miettinen and
Kesäniemi 1989, Miettinen et al 1989, Gylling et al 1994) found no
association between these. Thus it seems that serum cholesterol levels are
more dependent on cholesterol absorption than synthesis. However, in type 2
DM cholesterol synthesis seems to have an inverse association with LDL
cholesterol level (Gylling and Miettinen 1996a, Gylling and Miettinen 1997).
2.4.3 Cholesterol and lipoprotein metabolism
Few studies have investigated the associations between cholesterol
synthesis and absorption on the one hand, and production and catabolism of
lipoproteins on the other hand. Miettinen et al (1987) reported no clear
correlations between the synthesis and elimination of cholesterol and, on
another side, concentration and catabolism of LDL apo B, which suggests
that the changes in cholesterol metabolism are compensated in the liver
without affecting the metabolism of LDL apo B. However, bile acid
malabsorption enhanced both cholesterol synthesis and the catabolism of
LDL apo B, while cholesterol malabsorption caused by different mechanisms
only increased cholesterol synthesis but affected LDL apo B kinetics
inconsistently (Miettinen et al 1987). Later, other studies found positive
correlations between cholesterol synthesis rate and the catabolism of LDL
apo B, and between fractional cholesterol absorption and production of LDL
apo B (Miettinen et al 1992, Gylling et al 1994). Positive correlations found
recently between the hepatic secretion of VLDL apo B and indicators of
cholesterol synthesis suggest that the production of apo B from the liver is
regulated by cholesterol synthesis rate (Watts et al 1995c, Riches et al 1997).
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2.5 Statin treatment
The first statin, initially called mevinolin, was discovered over twenty years
ago (Endo et al 1976, Alberts et al 1980). Statins are specific inhibitors of
HMG-CoA reductase, the rate limiting enzyme in cholesterol synthesis.
Inhibition of cholesterol synthesis accelerates the activity of LDL receptors
(Kovanen et al 1981, Traber and Kayden 1984, Berglund et al 1989, Raveh
et al 1990, Reihner et al 1990, Angelin 1991). However, the clearance of LDL
particles from the circulation has been reported to either increase (Kovanen
et al 1981, Bilheimer et al 1983, Malmendier et al 1989, Vega and Grundy
1991, Gylling and Miettinen 1996b), decrease (Vega et al 1988), or remain
unchanged (Grundy and Vega 1985, Arad et al 1990, Vega et al 1990,
Cuchel et al 1997) during statin treatment. Lowered production of LDL apo B
during statin treatment has been more consistently reported (Kovanen et al
1981, Grundy and Vega 1985, Vega et al 1988, Arad et al 1990, Vega et al
1990, Gaw et al 1993, Gylling and Miettinen 1996b, Cuchel et al 1997), and it
is considered to result from increased clearance of VLDL and IDL particles by
LDL receptors before conversion into LDL. However, in combined
hyperlipidemia a rise in the catabolic rate of LDL apo B without a significant
change in its production during statin treatment has been demonstrated
(Vega and Grundy 1991, Parhofer et al 1993, Schonfeld et al 1998). Some
studies have also shown decreased production of VLDL apo B by the liver
during statin treatment (Cortner et al 1993, Watts et al 1995b, Burnett et al
1997), possibly due to the reduction in cholesterol synthesis regulating the
production of apo B in the liver to some extent (Thompson et al 1996, Riches
et al 1997, Watts et al 1997). Furthermore, the basal rate of lipoprotein
metabolism and the dose of the statin probably affect the changes caused by
statins (Aguilar-Salinas et al 1998). In addition to increased LDL receptor
activity and decreased production of LDL apo B, statin treatment was recently
shown to decrease the affinity of LDL particles for the LDL receptor, which
could explain why the catabolism of LDL is only modestly increased by statins
(Berglund et al 1998). Thus, the mechanism by which statins lower levels of
LDL cholesterol seems to be more complicated than just up-regulation of LDL
receptors. The effect of statins on the sialic acid content of lipoproteins has
not been studied, whereas fibrates seem to diminish it (Anber et al 1997,
Millar et al 1999).
Nowadays, statins are widely used in the treatment of hypercholesterolemia.
Their efficiency in lowering serum and LDL cholesterol levels and thus the
morbidity and mortality related to CAD has been confirmed in many large
studies (Scandinavian Simvastatin Survival Study Group 1994, West of
Scotland Coronary Prevention Study Group 1995, Cholesterol and Recurrent
Events Trial Investigators 1996, AFCAPS/TexCAPS Research Group 1998,
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The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group 1998). They have also been shown to inhibit progression of
atherosclerosis in coronary arteries (Watanabe et al 1988, Khachadurian et al
1991, Kroon et al 1993). Lately, other mechanisms apart from the lowering of
cholesterol levels have been suggested to account partially for the good and
relatively rapid efficiency of statins in diminishing the incidence of CAD
events and CAD mortality, e.g. inhibition of the action of macrophages,
promotion of endothelial relaxation, and decrease in hypercoagulability by
affecting multiple factors associated with blood clotting (Vaughan et al 1996).
Out of LDL subfractions, statin treatment reduced only the concentration of
the most dense fraction in one study (Nozaki et al 1990), but evenly the
concentrations of all subfractions in another study (Yuan et al 1991). The
ratio of cholesterol to apo B in LDL has been reported to either decrease
(Nozaki et al 1990) or remain unchanged (Vega et al 1990, Yuan et al 1991,
Gylling and Miettinen 1996b) during statin therapy, whereas the mean size of
LDL particles enlarges (Yuan et al 1991, Zhao et al 1991) or keeps
unchanged (Vega et al 1990, Cheung et al 1993, Superko et al 1997).
Overall, LDL subclass pattern seems to persist during statin treatment (Vega
et al 1990, Franceschini et al 1994, Homma et al 1995, Superko et al 1997).
Statins have been shown to diminish the ratios of cholesterol precursor
sterols to cholesterol and elevate the ratios of plant sterols, reflecting
decreased synthesis and increased intestinal absorption of cholesterol
(Vanhanen and Miettinen 1995, Gylling and Miettinen 1996b). A high ratio of
cholestanol to cholesterol at baseline, indicating low cholesterol synthesis
rate, predicts poor response to statin treatment (Miettinen et al 1998).
While statins efficaciously reduce the concentrations of serum and LDL
cholesterol, their effect on serum Lp(a) levels is controversial. Many studies
have found no change in Lp(a) levels during statin treatment (Berg and Leren
1989, Fieseler et al 1991, Cheung et al 1993, Hunninghake et al 1993,
Haffner et al 1995, Raal et al 1997), some have reported even elevated
levels (Jürgens et al 1989, Kostner et al 1989, Broijersen et al 1994, Branchi
et al 1995), while also lowered levels have been described (Leren et al 1992).
The importance of the apparent uneffectiveness of statins on high Lp(a)
levels is unclear, but possibly subjects with very high levels would benefit
from reduction of Lp(a).
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3 AIMS OF THE STUDY
The deposition of cholesterol from lipoproteins to artery walls leads to
atherosclerosis, and this is undoubtedly mediated by multiple mechanisms.
According to data from previous studies referred to above, sialic acid as
structural part of LDL particles seems to have a role in the evaluation of the
atherogenic potential of LDL. A low sialic acid content in LDL of CAD patients
has been reported in many but not all studies, leaving the subject
controversial. Serum total and LDL cholesterol levels are regulated in general
by the metabolism of cholesterol and LDL apo B, but there is no information
on whether the sialic acid content of LDL is related with this. There is some
evidence that LDL sialic acid content has associations with serum and
lipoprotein lipid concentrations, but former data are not consistent, and there
are no data on the connections of sialic acid with lipid and apo B contents in
LDL subfractions. Furthermore, the effect of statins, widely used as
efficacious hypocholesterolemic agents, on LDL sialic acid content has not
been studied.
Thus, the aims of this study were:
• To evaluate the relations of LDL sialic acid content with the concentrations
of lipids and lipoproteins, and with the composition of LDL particles
 
• To investigate the sialic acid content of LDL in CAD and in conditions
associated with an increased risk of CAD, namely type 2 DM and type IIa
and IIb hyperlipidemia
 
• To find out possible associations of LDL sialic acid content with the
metabolism of LDL, and with synthesis and absorption of cholesterol
 
• To study the effect of statin treatment on LDL sialic acid content
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4 PATIENTS AND METHODS
4.1 Patients and study designs
Subjects for the studies were collected from the outpatient clinics of Helsinki
University Central Hospital. All subjects volunteered for the study and gave
an informed consent. The study protocols were accepted by the Ethics
Committee of this hospital. Clinical characteristics of the study subjects are
given in Table 1.
Table 1. Clinical characteristics of the study patients. BMI = body mass index
___________________________________________________________________________
Variables Study I_______ Study II______ Study III Study IV
DM+ DM- IIa IIb
___________________________________________________________________________
Number of subjects 20 10 22 21 98 26
Males/females 20/0 10/0 18/4 12/9 45/53 21/5
Age, years 56.0±1.2 54.2±2.7 53.5±2.2 58.2±1.1 54.0±0.7 55.8±1.6
BMI, kg/m2 28.9±0.9 28.2±1.1 27.8±1.0 28.6±0.9 27.1±0.4 28.8±0.9
___________________________________________________________________________
mean±SE
Study I, type 2 diabetes mellitus. The study group consisted of 20 men
with type 2 DM (DM+) and 10 non-diabetic men of the same age (DM-). The
diagnosis of type 2 DM was based on repeated fasting blood glucose level
≥7.0 mmol/l (WHO Consultation 1998). The duration of DM was 4.5±1.0
(mean±SE) years, and diabetes control was moderate with a mean glycated
hemoglobin value of 7.8±0.5%. None of the diabetics had insulin treatment, 8
were on diet only, 9 on glibenclamide, 1 on metformin, and 2 on the
combination of glibenclamide and metformin. The medications were
unchanged during the study. The presence of clinically evident CAD was
found in 13 diabetic subjects verified by coronary angiography (n=11),
exercise bicycle test (n=1) (ST-segment or T-wave changes with typical chest
pain), or with a history of myocardial infarction (n=1). The absence of CAD
was observed in 7 patients verified by angiography (n=2) or exercise bicycle
test (n=5). Out of the 10 non-diabetic men, 4 had CAD, of which 2 were
verified angiographically and 2 with a history of myocardial infarction. In the
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remaining 6 subjects, CAD was excluded by exercise bicycle test. Three DM
patients and 1 control subject were smokers.
Study II, type IIa and IIb hyperlipidemia. Forty-three patients, 30 men
and 13 women, were divided into two groups according to their lipid
phenotype obtained in two fasting serum samples a week apart. Twenty-two
subjects (18 men and 4 women) were categorized into the primary moderate
hypercholesterolemia group (type IIa; LDL cholesterol 3.5-5.5 mmol/l and
serum triglycerides <2.5 mmol/l), and 21 subjects (12 men and 9 women) into
the combined hyperlipidemia group (type IIb; LDL cholesterol 3.5-5.5 mmol/l
and serum triglycerides >2.5 mmol/l). Thirty-three subjects had CAD verified
either by exercise bicycle test (n=4), or by coronary angiography and/or a
history of myocardial infarction at least six months prior to the study (n=29),
while the remaining 10 subjects had no evidence of CAD in exercise bicycle
test. One patient in the IIa group had oral medication for type 2 DM, and 3 in
IIa and 4 in IIb group had DM treated only with diet. Eleven volunteer subjects
from IIa group and 16 from IIb group participated in the kinetic studies.
Study III, coronary artery disease. Ninety-eight subjects, 53 women and
45 men, were recruited for the study. Fifty-six subjects (CAD+), 30 men and
26 women, had CAD diagnosed either by a history of myocardial infarction
(n=37), by coronary angiography (n=14) or by exercise bicycle test (n=5),
while the remaining 42 subjects (CAD-) had no symptoms or manifestations
of CAD in clinical interview and examination, or in ECG. None of the subjects
had DM. They had been councelled a low-fat low-cholesterol diet at least six
months earlier, and they kept the diet unchanged. Forty-four subjects were
on beta-blocking agents, 6 subjects were taking thiazide diuretics, and 15 out
of the 53 women had hormone replacement therapy. Twenty-four subjects
were current smokers. In order to examine differences in CAD+ and CAD-
subjects at different sialic acid levels, both CAD+ and CAD- subjects were
divided into quartiles according to the sialic acid to apo B ratios of total and
dense LDL, with equal numbers of subjects in each quartile. The quartiles are
designated as Q1, Q2, Q3 and Q4 from low to high sialic acid ratios. Fifty-eight
volunteers out of the 98 subjects participated in the kinetic study.
Study IV, statin treatment. The study group consisted of 26 moderately
hypercholesterolemic patients (LDL cholesterol >3.3 mmol/l), 21 males and 5
females. All except 4 patients had CAD verified either by angiography and/or
a history of acute myocardial infarction at least six months before the study
(n=20), or by exercise bicycle test (n=2). Five patients had DM treated with
diet only. Sixteen patients were on beta-blocker treatment at the time of the
study, and 2 used thiazide diuretics for hypertension. The medications were
unchanged during the study. None of the women used hormone replacement
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therapy. Four patients were current smokers. After recruitment to the study,
possible lipid lowering medication was discontinued, and the patients started
a low-fat low-cholesterol diet, containing a scheduled amount of 30 energy-%
of fat and less than 300 mg/day of cholesterol. After six weeks on the diet,
baseline lipid analyses and metabolic studies were performed. Subsequently,
the patients continued the diet and started statin treatment, with 10 patients
receiving on the average 0.2 mg/day (0.1-0.3 mg) of cerivastatin, 9 patients
on the average 30 mg/day (20-40 mg) of fluvastatin, and 7 patients 20
mg/day of simvastatin. When the patients had been on statins for two to
three months, the lipid analyses and metabolic studies were repeated.
Thirteen subjects volunteered to participate in both kinetic studies.
None of the subjects in the studies had gastrointestinal, liver, renal, or thyroid
disease, except 3 subjects in Study III who had thyroxin treatment for
hypothyroidism, and had been euthyroid for at least two years before the
study. No one had tendon or cutaneous xanthomas or xanthelasmas. The
subjects were not on any lipid lowering medication at the baseline of the
studies.
4.2 Methods
4.2.1 Separation of lipoproteins
Serum samples were drawn after a 12-hour fast. Serum lipoproteins were
separated with serial ultracentrifugations into VLDL, IDL, LDL and HDL
(Havel et al 1955, Lipid Research Clinics Program 1982). After the separation
of total LDL (d = 1.019-1.063 g/ml), it was fractionated into three subfractions:
light (d = 1.019-1.036 g/ml), dense (d = 1.037-1.055 g/ml) and very dense
(d = 1.056-1.063 g/ml), by density gradient ultracentrifugation. The density
gradient was prepared in a 40-ml polyallomer Quick-Seal tube as follows:
11.3 ml of NaBr-NaCl salt solution (d = 1.065 g/ml) was carefully overlayered
by 11.3 ml of LDL (d = 1.04 g/ml), which in turn was overlayered by NaBr-
NaCl salt solution of d = 1.025 g/ml. The fractionation was completed by
ultracentrifugation (44 h at 58,000 rpm at +10°C) in a Ti 60 fixed-angle rotor
(Beckman Instruments).
4.2.2 Analyses of lipids, apolipoproteins and non-cholesterol
sterols
The concentrations of total and free cholesterol, triglycerides, and
phospholipids were analyzed from serum and from all lipoproteins with
36
commercial kits (Boehringer Diagnostica, Mannheim, Germany; and Wako
Chemicals GMBH, Neuss, Germany). Concentrations of apo B, apo A-I and
Lp(a) were analyzed with commercial kits (Orion Diagnostica, Espoo, Finland;
and Mercodia AB, Uppsala, Sweden) from serum, and that of apo B also from
total LDL and its subfractions. The coefficients of variation of the analyses
were <2% for lipids and <5% for apolipoproteins. Mean values of three
analyses from samples taken at one-week intervals are given for serum and
lipoprotein lipids and apolipoproteins. Recoveries for serum lipoprotein lipid
concentrations were always >90% and mostly >95%. In LDL density gradient
the recovery percents were occasionally more variable, and therefore the lipid
concentrations of LDL subfractions are given recovery corrected except in
Study I. Apo E phenotypes were analyzed by electrophoresis and isoelectric
focusing from serum (Havekes et al 1987). Total protein contents of the
lipoproteins were analyzed in Study II with the Lowry method (Lowry et al
1951).
Serum non-cholesterol sterols, including the cholesterol precursor sterols
∆8-lathosterol, desmosterol and lathosterol, the plant sterols campesterol and
sitosterol, and the cholesterol metabolite cholestanol, were determined from
non-saponifiable serum extract by gas-liquid chromatography on a 50-m long
SE-30 capillary column (Hewlett Packard, Ultra I column) (Miettinen 1988).
Being transported in serum by lipoproteins similarly to cholesterol, the
concentrations of the non-cholesterol sterols are highly dependent on serum
cholesterol levels. Thus the values are expressed as 102 x mmol/mol of
serum cholesterol, i.e. as ratios to cholesterol, to eliminate the effect of
variation in cholesterol levels.
4.2.3 Analysis of sialic acids
The concentration of sialic acids in total LDL and its subfractions, and in
Study II, also in VLDL, IDL and HDL, was analyzed according to the
resorcinol method by Svennerholm (1957) modified by Miettinen and Takki-
Luukkainen (1959), using N-acetylneuraminic acid (Sigma Chemical
Company, St Louis, MO, USA) as the standard. Shortly, sialic acids were first
dissociated from LDL by acid hydrolysis in 0.1-N H2SO4 at +80°C for one
hour. Subsequently, resorcinol-hydrochloric acid was used to cause a color
reaction with sialic acid. Finally, the pigment was extracted with butyl acetate
and its intensity measured with a spectrophotometer. In Study I, the sialic
acid concentration was determined with the thiobarbituric acid assay (Warren
1959a) in addition to the resorcinol method, and the results were consistent
with each other with a correlation coefficient of r=0.960 (n=16). Because of
the high dependence of LDL sialic acid concentration on LDL apo B
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concentration (Fontaine and Malmendier 1978), observed also in the present
study, the sialic acid content of total LDL and its subfractions is given as the
ratio of sialic acid to apo B and not as sialic acid concentration as in all earlier
studies, and it is designated as the sialic acid ratio. In Study II, the sialic acid
content of lipoproteins in the comparison of VLDL, IDL, LDL and HDL is given
as the ratio of sialic acid to total protein.
4.2.4 Lipoprotein kinetic studies
For the kinetic studies, 50 ml of fasting EDTA plasma was drawn, and
autologous total LDL and HDL were separated by serial density
ultracentrifugations. Apo A-I was isolated from HDL as described in detail by
Gylling et al (1992). Briefly, HDL was incubated with guanidine hydrochloride,
dialyzed, density-adjusted with NaBr, and ultracentrifugated, after which pure
apo A-I was collected from the bottom and extensively dialyzed. LDL was
fractionated by serial density ultracentrifugations into three subclasses as
previously described, and dialyzed extensively. Dense LDL apo B and apo
A-I were iodinated with 125I, and total LDL apo B with 131I by a modification of
the iodine-monochloride method (McFarlane 1958, Bilheimer et al 1972).
Three days before injection the subjects started to take peroral potassium
iodide to protect the thyroid gland. Approximately 1 mg of a mixture of the
labeled total and dense LDL apo B and apo A-I were mixed with 5% human
serum albumin, filtered, and injected. The total amount of radioactivity did not
exceed 60 µCi.
After the injection, serial blood samples of 10 ml were collected for 14 days
and counted. The die-away curves were constructed from plasma for 131I-LDL
and after ultracentrifugal separation for 125I-dense LDL and 125I-HDL.
Fractional catabolic rates (FCRs) for total and dense LDL apo B and HDL apo
A-I were determined using a two-pool model (Matthews 1957). Transport rate
(TR) was calculated by multiplying FCR by the pool size. Pool size was the
apoprotein plasma concentration multiplied by plasma volume, which was
calculated to be 4.5% of body weight. FCR is expressed in pools/day and
reflects the rate at which the lipoprotein is removed from the circulation, while
TR, expressed in mg/kg/day, reflects the rate of production of the lipoprotein.
4.2.5 Statistics
Analyses were performed with Microsoft Excel, Primer of Biostatistics, and
Biomedical Data Program (BMDP). Statistical significancies of differences
between groups were tested with analysis of variance (ANOVA) and, when
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appropriate, with Student's two-tailed t-test. X2-test or Fisher exact test was
used for nominal scale variables. In Study IV, paired t-test was used to
determine the change caused by the statin treatment. Correlations were
analyzed by calculating Pearson’s product-moment correlation coefficient for
normally distributed variables. In case of skewed distributions, either
logarithmic transformations or Spearman's rank-order correlation coefficient
was applied. Values are given as mean±SE. A P-value of less than 0.05 was
considered statistically significant.
In Study I, the variability in the FCR for LDL apo B was examined with a
multiple linear regression analysis with the presence of DM, LDL and HDL
cholesterol and serum triglyceride concentrations, and LDL sialic acid ratio as
the independent variables. Similarly, another linear regression model was
made with FCR for dense LDL apo B as the dependent variable, and the
presence of DM and cholesterol and triglyceride concentrations and the sialic
acid ratio of dense LDL as the independent variables. In Study III, a stepwise
logistic regression analysis was carried out with the presence of CAD as the
dependent variable, and LDL cholesterol and triglyceride concentrations, LDL
sialic acid ratio, and FCR and TR for LDL apo B as the independent
variables. To explain the variability in LDL sialic acid ratio, a stepwise
regression analysis was performed with the presence of CAD, the
concentrations of cholesterol and triglycerides in LDL, and FCR and TR for
LDL apo B as the independent variables.
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5 RESULTS
Table 2. Serum and lipoprotein lipid and apo B levels.
___________________________________________________________________________
Variables Study I_______   Study II______     Study III Study IV
DM+  DM-   IIa   IIb
n=20  n=10   n=22   n=21     n=98 n=26
___________________________________________________________________________
Serum cholesterol,
mmol/l 6.10±0.16  5.93±0.23   6.84±0.17* 7.39±0.17     6.31±0.11 7.06±0.16
Serum triglycerides,
mmol/l 2.90±0.40*  1.69±0.18   1.78±0.09   3.43±0.18     1.89±0.10 2.50±0.22
LDL cholesterol,
mmol/l 3.44±0.14  3.49±0.19   4.38±0.11   4.16±0.13     3.75±0.08 4.33±0.09
LDL apo B,
mg/dl 72.7±2.5  72.5±3.3   99.7±2.8   99.8±2.5     86.8±2.1 100.9±2.3
HDL cholesterol,
mmol/l 0.98±0.04  1.21±0.13   1.18±0.06   1.06±0.04     1.23±0.03 1.12±0.04
___________________________________________________________________________
mean±SE. * P<0.05 for difference between groups within study sections.
5.1 Type 2 diabetes mellitus (Study I)
Serum and lipoprotein lipids. The presence or type of hypoglycemic
therapy had no effect on serum lipid and sialic acid levels or metabolic
parameters. The diabetic subjects had higher triglyceride levels in serum
(Table 2) and VLDL than the non-diabetics, and a larger proportion of
triglycerides in all LDL subfractions. Cholesterol and apo B concentrations
were similar between diabetics and non-diabetics in total LDL and all its
subfractions.
LDL sialic acid ratio. The sialic acid per apo B ratio (mass/mass ratio,
µg/mg) was higher in the diabetics than in the non-diabetics in total LDL and
all its subfractions (Figure 4). There were no correlations between sialic acid
ratios and serum triglyceride or LDL cholesterol levels. In the diabetic
subjects, the sialic acid ratios were similar between CAD- (n=7) and CAD+
subjects (n=13) in total LDL and in the subfractions, being e.g. 65.9±16.1 and
69.2±7.9 µg/mg, respectively, in dense LDL. In the non-diabetics, there was a
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tendency towards lower ratios in CAD+ subjects; for instance, in dense LDL
the ratio was 46.5±9.8 µg/mg in CAD- (n=6) and 31.9±5.2 µg/mg in CAD+
(n=4), but the difference between the ratios was not significant.
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Figure 4. The sialic acid to apo B ratios of total LDL and its light, dense
and very dense subfractions in subjects without (DM-, n=10) and with DM
(DM+, n=20). * P<0.05; *** P<0.001 for difference between DM- and
DM+.
LDL metabolism. FCRs for both total and dense LDL apo B were more
elevated in the diabetic subjects and so was the TR for dense LDL apo B,
indicating a higher turnover rate for dense LDL in the diabetics (Table 3).
Table 3. Kinetics of total and dense LDL apo B in non-diabetic (DM-) and
type 2 diabetes mellitus (DM+) patients. FCR = fractional catabolic rate,
TR = transport rate.
___________________________________________________________
Variables DM- DM+
n=10 n=20
___________________________________________________________
Total LDL
     FCR, pools/d 0.283±0.010 0.329±0.010 **
     TR, mg/kg/d 7.8±0.4 8.6±0.5
Dense LDL
     FCR, pools/d 0.298±0.031 0.399±0.028 *
     TR, mg/kg/d 5.0±0.6 6.8±0.6 *
___________________________________________________________
mean±SE. * P<0.05, ** P<0.01
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FCR for total LDL apo B had a positive correlation with serum triglyceride
level (r=0.631, P<0.001) and a negative correlation with LDL cholesterol level
(r=-0.654, P<0.001) in the whole study group. FCR for dense LDL apo B was
positively correlated with the sialic acid ratio of dense LDL (Figure 5). In the
multiple linear regression analysis, the variability in FCR for total LDL apo B
was explained by LDL cholesterol and serum triglyceride concentrations, and
the variability in FCR for dense LDL apo B was explained only by dense LDL
cholesterol concentration.
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Figure 5. Correlation between fractional catabolic rate for dense LDL apo
B and dense LDL sialic acid to apo B ratio (log scale) in DM+ and DM-
subjects. n=30, y = 0.603x + 1.49, r=0.485, P<0.05.
5.2 Type IIa and IIb hyperlipidemia (Study II)
Serum and lipoprotein lipids. In addition to higher serum triglyceride
levels, the subjects with IIb hyperlipidemia also had higher cholesterol (Table
2) and phospholipid concentrations in serum, VLDL and IDL, and higher
triglyceride levels in all lipoproteins than the IIa hyperlipidemia subjects. In the
LDL subfractions, the concentrations of cholesterol, phospholipids and apo B
were lower in light LDL and higher in dense and very dense LDL of IIb than
IIa subjects, and the concentration of triglycerides similar in light but higher in
dense and very dense LDL of IIb subjects (Table 4). The light LDL particles of
IIb subjects had less cholesterol and phospholipids per apo B, and very
dense particles less triglycerides and phospholipids per apo B than those of
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IIa subjects, while the composition of the dense LDL particles were alike in
the two groups (Table 4).
Table 4. Lipid and apo B concentrations and lipid composition per apo B
in light, dense and very dense LDL subfractions in type IIa and IIb
hyperlipidemia patients.
___________________________________________________________
Variables IIa IIb
n=22 n=21
___________________________________________________________
Light LDL
     cholesterol, mmol/l 2.10±0.16 1.36±0.12 ***
     triglycerides, mmol/l 0.17±0.01 0.17±0.01
     apo B, mg/dl 44.5±3.6 31.8±2.5 **
Dense LDL
     cholesterol, mmol/l 2.07±0.14 2.43±0.12
     triglycerides, mmol/l 0.12±0.01 0.18±0.01 ***
     apo B, mg/dl 50.6±3.3 60.6±1.9 *
Very dense LDL
     cholesterol, mmol/l 0.21±0.02 0.36±0.06 *
     triglycerides, mmol/l 0.025±0.002 0.039±0.003 **
     apo B, mg/dl 4.6±0.4 7.5±0.6***
Light LDL
     cholesterol/apo B 1.96±0.02 1.75±0.04 ***
     triglycerides/apo B 0.42±0.03 0.48±0.03
     phospholipids/apo B 1.26±0.02 1.13±0.02 ***
Dense LDL
     cholesterol/apo B 1.68±0.03 1.68±0.10
     triglycerides/apo B 0.26±0.01 0.25±0.01
     phospholipids/apo B 1.05±0.02 0.98±0.04
Very dense LDL
     cholesterol/apo B 1.98±0.09 1.88±0.14
     triglycerides/apo B 0.60±0.05 0.44±0.03 **
     phospholipids/apo B 1.76±0.17 1.31±0.09 *
___________________________________________________________
mean±SE. * P<0.05, ** P<0.01, *** P<0.001
The percentage of esterified cholesterol out of total cholesterol was higher in
total, dense and very dense LDL of IIb than IIa subjects. Apo E phenotype
distributions were similar in IIa and IIb groups. The kinetics of total LDL apo B
were comparable in IIa and IIb subjects, but the TR for dense LDL apo B was
higher in IIb as compared with IIa (5.55±0.37 vs 4.20±0.29 mg/kg/day,
P<0.01).
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Lipoprotein sialic acid ratios. The ratio of sialic acid to total protein
lowered gradually with increasing lipoprotein density, being highest in VLDL
and IDL, intermediate in LDL and lowest in HDL (Figure 6). In VLDL and IDL,
the ratio was lower for IIb than IIa subjects, but similar in LDL and HDL
between the groups. In LDL subfractions, the ratio of sialic acid to apo B was
lower in the dense and very dense LDL of IIb than IIa subjects (Figure 7).
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Figure 6. The sialic acid to total protein ratios of VLDL, IDL, LDL and
HDL in the combined IIa and IIb groups (n=43). *** P<0.001 from the
preceding lipoprotein density class.
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Figure 7. The sialic acid to apo B ratios of total LDL and its light, dense
and very dense subfractions in subjects with type IIa (n=22) and IIb
(n=21) hyperlipidemia. ** P<0.01; *** P<0.001 for difference between IIa
and IIb.
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CAD+ and -CAD subjects had similar sialic acid ratios in IIa and IIb groups
separately, and when the groups were combined, the ratio did not differ
between CAD+ and CAD- subjects in total, light or dense LDL, but was higher
in the very dense LDL of CAD (n=33) than non-CAD (n=10) subjects
(178.9±20.1 and 129.7±12.6 µg/mg, respectively, P=0.04). This is
presumably associated with the presence of Lp(a) in this fraction, and serum
Lp(a) levels were unsignificantly higher in CAD+ than CAD- subjects (345±59
vs 199±55 U/l, respectively, P=0.08). The 8 subjects with DM had similar LDL
sialic acid ratios than the rest of the subjects.
Correlations. In IIa and IIb hyperlipidemia groups combined, the sialic acid
ratios of dense and very dense LDL were negatively related with their
cholesterol (r=-0.526 and r=-0.597, respectively, P<0.001 for both) and
triglyceride concentrations (r=-0.486 and r=-0.463, respectively, P<0.01 for
both), and with the TR for dense LDL apo B (r=-0.575 and r=-0.624, P<0.01
for both). TR for dense LDL apo B was positively correlated with the
cholesterol concentration of dense LDL, serum triglyceride level, and the
esterification percentage of total LDL cholesterol (r=0.675, P<0.001).
5.3 Coronary artery disease (Study III)
Clinical characteristics and LDL sialic acid ratios. Sialic acid ratios of
total LDL and its subfractions did not differ between males and females, or
smokers and non-smokers. The use of thiazide diuretics or, in females,
hormone replacement therapy, had no effect on LDL sialic acid ratios. In the
whole study group and in the CAD+ group, LDL sialic acid ratios were not
affected by beta-blocker treatment, but in hypertensive CAD- subjects on
beta-blockers (n=6) the sialic acid ratio was lower in total LDL than in CAD-
subjects not on beta-blockers (n=34) (33.5±3.1 vs 44.9±2.3 µg/mg,
respectively, P<0.01). CAD+ and CAD- subjects were of similar age, body
mass index (BMI), and sex and apo E phenotype distributions.
LDL sialic acid ratio and CAD. LDL cholesterol concentration was higher
in CAD+ than CAD- subjects, while levels of HDL cholesterol, serum
triglycerides and Lp(a) were similar between the groups. The mean sialic acid
ratios of total LDL and its dense and very dense subfractions were lower in
CAD+ than CAD- subjects (Figure 8). When the CAD+ and CAD- subjects
were divided into quartiles by LDL sialic acid ratio, the ratios of both total and
dense LDL were markedly lower in CAD+ than CAD- subjects of the three
highest quartiles but not in those of the lowest quartile. However, in the
stepwise regression analysis with the presence of CAD as the dependent
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variable, only LDL cholesterol concentration and not its sialic acid ratio
explained its variability.
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Figure 8. The sialic acid to apo B ratios of total LDL and its light, dense
and very dense subfractions in subjects without (CAD-, n=42) and with
CAD (CAD+, n=56). * P<0.05, ** P<0.01.
Serum and lipoprotein lipids. In general, in serum and in total, light and
dense LDL all the lipid concentrations had negative correlations with LDL
sialic acid ratio (Table 5), while the concentrations of HDL lipids and Lp(a)
were not associated with it. The ratios of cholesterol and phospholipids per
apo B were positively associated with the sialic acid ratio in total LDL, and in
the subfraction analysis this was seen in the dense and very dense
subfractions (Table 5).
Table 5. Correlation coefficients of total LDL sialic acid to apo B ratio with lipid and apo B
concentrations and lipid to apo B ratios of total LDL and its light, dense and very dense
subfractions. n=98.
___________________________________________________________________________
_________________Sialic acid to apo B ratio_________________
Variables Total LDL   Light LDL     Dense LDL Very dense LDL
___________________________________________________________________________
cholesterol -0.377 ***   -0.126     -0.305 ** 0.066
triglycerides -0.296 **   -0.274 **     -0.225 * -0.003
apo B -0.526 ***   -0.246 *     -0.372 *** -0.144
cholesterol/apo B 0.268 **   0.188     0.227 * 0.351 ***
triglycerides/apo B 0.226 *   0.062     0.125 0.132
phospholipids/apo B 0.385 ***   0.192     0.302 ** 0.395 ***
___________________________________________________________________________
* P<0.05, ** P<0.01, *** P<0.001
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Non-cholesterol sterols and LDL sialic acid ratio. The ratios of non-
cholesterol sterols to cholesterol did not differ between CAD- and CAD+
subjects, and were not related to the sialic acid ratio of total LDL. However,
the sialic acid ratio of dense LDL was correlated negatively with
∆8-lathosterol, desmosterol and lathosterol ratios (r=-0.389, P<0.001;
r=-0.244, P<0.05; and r=-0.311, P<0.01, respectively), and positively with
campesterol, sitosterol and cholestanol ratios (r=0.219, P<0.05; r=0.239,
P<0.05; and r=0.407, P<0.001, respectively). At high dense LDL sialic acid
ratios (>40 µg/mg), CAD+ subjects had lower lathosterol ratios than CAD-
subjects (135.9±14.4 vs 191.0±15.4, P<0.05).
LDL kinetics and sialic acid ratio. The 58 subjects participating in the
kinetic studies had higher BMI and serum triglyceride concentration, and
higher mean sialic acid ratio in total LDL than the non-participants (43.8±1.7
vs 36.0±0.8 µg/mg, P<0.001). Similarly to the total study group, in the
participants of the kinetic study cholesterol and apo B concentrations of both
total and dense LDL had inverse associations with the sialic acid ratios of
total and dense LDL. The sialic acid ratios of total and dense LDL were
unrelated to the FCRs for total and dense LDL apo B, but they correlated
inversely with the TRs for both total and dense LDL apo B (Table 6, Figure
9). In addition, the TR for dense LDL apo B had significant positive
correlations with ∆8-lathosterol and lathosterol ratios (r=0.322 and r=0.307,
respectively, P<0.05 for both), and a negative correlation with cholestanol
ratio (r=-0.410, P<0.01). The CAD+ subjects had higher TRs for total and
Table 6. The correlation coefficients of kinetic parameters
of total and dense LDL apo B with sialic acid to apo B
ratios of total and dense LDL. FCR = fractional catabolic
rate, TR = transport rate. n=58.
_______________________________________________
___Sialic acid to apo B ratio__
Variables total LDL dense LDL
_______________________________________________
Total LDL
     apo B -0.583   *** -0.468   ***
     FCR 0.241 0.158
     TR -0.384   ** -0.305   *
Dense LDL
     apo B -0.476   *** -0.582   ***
     FCR -0.003 -0.174
     TR -0.351   ** -0.456   ***
_______________________________________________
mean±SE. * P<0.05, ** P<0.01, *** P<0.001
47
dense LDL apo B - this was seen only in the two highest quartiles - while the
FCRs did not differ between CAD+ and CAD- subjects. The stepwise
regression analysis showed that both the TR and the FCR for total LDL apo B
accounted for the variability in LDL sialic acid ratio, but the presence of CAD
and the concentrations of cholesterol and triglycerides in LDL did not affect it.
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Figure 9. Correlation between dense LDL sialic acid to apo B ratio and
transport rate (TR) for dense LDL apo B. n=58, y = -0.053 x + 6.36,
r=-0.456, P<0.001.
5.4 Statin treatment (Study IV)
Serum and lipoprotein lipids. No differences were seen at baseline and
in the changes caused by the various statins on lipids or sialic acids, and thus
the groups with the three different statins (fluvastatin, simvastatin,
cerivastatin) were examined together. The concentrations of cholesterol,
triglycerides and phospholipids were significantly lowered in serum, VLDL,
IDL and LDL during statin treatment, and the relative proportion of cholesterol
diminished in all apo B -containing lipoproteins. The concentrations of lipids
and apo B decreased remarkably also in all the LDL subfractions during
statin treatment, and the higher the baseline lipid levels were, the more
markedly did they decrease. The lipid/apo B ratios of LDL subfractions did
not change, indicating that statins decreased only the number and did not
change the composition of LDL particles.
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LDL sialic acid ratio. The sialic acid ratio increased significantly in total
LDL and its three subfractions during statin treatment (Figure 10). The post-
treatment ratios did not vary much between the groups treated with different
statins, and the change was significant in total LDL for all the statin groups
separately (Figure 11).
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Figure 10. The sialic acid to apo B ratios of total LDL and its light, dense
and very dense subfractions before and during statin treatment. n=26, **
P<0.01; *** P<0.001 for change during statin treatment.
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Figure 11. The sialic acid to apo B ratio of total LDL before and during
treatment with cerivastatin (n=10), fluvastatin (n=9), and simvastatin
(n=7). * P<0.05.
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The sialic acid ratio was negatively correlated with cholesterol, phospholipid
and apo B concentrations in light and dense LDL subfractions both before
and during statin treatment, and with triglyceride concentration only during
statin treatment in all the subfractions. The changes in cholesterol,
phospholipid and apo B concentrations of dense LDL were negatively
correlated with the change in dense LDL sialic acid ratio (r=-0.501 for
cholesterol, r=-0.464 for phospholipids, and r=-0.667 for apo B, Figure 12). In
light and dense LDL, also the baseline sialic acid ratios were correlated with
the changes in cholesterol, phospholipid and apo B concentrations, and in
dense LDL additionally with the change in triglyceride concentration, so that
the lower the baseline sialic acid ratio was, the greater were the reductions in
the lipid and apo B concentrations (Figure 13).
Metabolism of LDL and cholesterol. FCRs for both total and dense LDL
apo B were increased, and TR for dense LDL apo B was decreased during
the statin treatment (Table 7). None of these variables were significantly
related to the sialic acid ratios or to the changes in them. The ratios of ∆8-
lathosterol, desmosterol and lathosterol to cholesterol diminished remarkably
during the statin treatment indicating decreased cholesterol synthesis, while
those of the plant sterols campesterol and sitosterol, and that of cholestanol
increased. The baseline ratios of the non-cholesterol sterols or the changes
in them were not connected with baseline sialic acid ratios nor with the
changes in sialic acid ratios during statin treatment.
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Figure 12. Correlation between the change in dense LDL sialic acid to
apo B ratio and the change in dense LDL apo B concentration. n=26,
y = -0.47x - 16.4, r=-0.667, P<0.001.
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Figure 13. Correlation between the baseline dense LDL sialic acid to apo
B ratio and the change in dense LDL apo B concentration. n=26,
y = 1.13x - 54.8, r=0.614, P<0.001.
Table 7. Apo B concentrations and kinetics of total and dense LDL apo B
before and during statin treatment. FCR = fractional catabolic rate, TR =
transport rate. n=13.
___________________________________________________________
Variables Before During
___________________________________________________________
Total LDL
     apo B, mg/dl 102.9±2.9 69.4±3.6 ***
     FCR, pools/d 0.277±0.011 0.380±0.010 **
     TR, mg/kg/d 12.7±0.48 11.6±0.77
Dense LDL
     apo B, mg/dl 63.6±4.4 37.9±3.3 ***
     FCR, pools/d 0.269±0.030 0.325±0.016 **
     TR, mg/kg/d 5.29±0.45 3.70±0.30 **
___________________________________________________________
mean±SE. ** P<0.01, *** P<0.001
51
6 DISCUSSION
6.1 General
The function of sialic acids in the metabolism of some glycoproteins (Stryer
1988) and their presence in lipoproteins, especially LDL (Swaminathan and
Aladjem 1976), make their role in atherosclerosis an intriguing subject. In the
late 1970’s a few studies reported that desialylation of LDL affects it
catabolism both in vitro (Filipovic and Buddecke 1979, Filipovic et al 1979)
and in vivo (Hendrix et al 1975, Malmendier et al 1980). Ten years later the
sialic acid content of LDL and its association with atherosclerosis came to
focus again, first in the numerous studies by Orekhov et al (1989, 1991b,
1992) and Tertov et al (1992a, 1992b), and later in the mid- to late 1990’s
also in studies by other groups (Ruelland et al 1993, Chappey et al 1995,
Grewal et al 1996, Anber et al 1997, Bartlett et al 1998, Harada et al 1998,
Millar et al 1999).
6.2 Clinical characteristics
In this study, the sialic acid ratios of total LDL and its subfractions did not
differ consistently between males and females. The mean age of the subjects
was around 55 years, and the females were practically all postmenopausal.
In Study III, 15 females out of 53 were on hormone replacement therapy, and
their LDL sialic acid ratios were similar to those of the women not taking
hormones and to those of the men. The age of the subjects was not
connected with LDL sialic acid ratio, nor were there consistent associations
between BMI and LDL sialic acid ratio. Current smokers had LDL sialic acid
ratios approximately corresponding to those of non-smokers. Apo E
phenotypes had no relation with LDL sialic acid content. Consequently, LDL
sialic acid ratio seems to be independent of demographic factors associated
with an increased risk of CAD, that is, male sex, old age, overweight, and
smoking, and also of apo E phenotypes 4/3 and 4/4 known to associate with
high CAD risk (Davignon et al 1988).
Beta-blocking agents are known to change plasma lipid profiles to a more
atherogenic direction (Lehtonen and Viikari 1979, Rohlfing and Brunzell
1986, Cruickshank 1990, Superko et al 1993), but they reduce CAD mortality
(Cruickshank 1990, Wikstrand et al 1991, Goldstein 1996). Overall, no
significant lipid variations were found between beta-blocker users and non-
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users in any of the present studies. However, in Study III in the CAD-
subgroup, beta-blocker users had lower total LDL sialic acid ratio than non-
users, while in the CAD+ subjects, who included most of the beta-blocker
users, there was no difference whatsoever in the sialic acid ratios between
users and non-users (39.0±1.6 vs 37.1±2.1 µg/mg for total LDL, respectively).
The small number of beta-blocker users in the CAD- subgroup (6 out of 42
subjects) does not allow to draw firm conclusions from the difference in this
group and, according to all available data, it is inferred that beta-blockers
seem not to have a significant effect on LDL sialic acid levels. Furthermore,
the use of thiazide diuretics, or the type of hypoglycemic therapy in DM
subjects did not affect the LDL sialic acid ratio.
6.3 Measurement of sialic acid ratio
The sialic acid content of lipoproteins was measured mainly with the
resorcinol method (Svennerholm 1957, Miettinen and Takki-Luukkainen
1959), and in Study I, also with the thiobarbituric acid assay (Warren 1959a).
Both methods are very practicable and reliable. Results from repeated
analyses with the resorcinol method were constant, with an intra-assay and
interassay variability of less than 5% in the present study. The resorcinol
method was preferably used because no time-consuming dialysis of the
samples is necessary, and the reagents are more stable than in the
thiobarbituric acid assay. Most other investigators have employed the
thiobarbituric acid assay, while the resorcinol method has been used by a
minority of groups (Fontaine and Malmendier 1975, Fontaine and Malmendier
1978, La Belle and Krauss 1990, Sobenin et al 1993, Tertov et al 1996b,
Millar et al 1999). The two methods, utilized in parallel in Study I, gave similar
results (r=0.960) in conformity with other reports (Orekhov et al 1991b,
Orekhov et al 1992).
The overall sialic acid to apo B ratios of LDL were on similar level in all the
subject groups, the mean values of the groups ranging from 36.7 to 43.7
µg/mg apo B for total LDL, excluding the diabetic subjects in Study I who had
a clearly higher ratio (mean of 62.3 µg/mg). These levels were close to those
reported in some studies (Orekhov et al 1989, La Belle and Krauss 1990,
Orekhov et al 1991b, Grewal et al 1996), but markedly higher than in most
other papers (Maruhama et al 1983, Orekhov et al 1992, Tertov et al 1992a,
Ruelland et al 1993, Sobenin et al 1993, Tertov et al 1993, Chappey et al
1995, Myara et al 1995, Ruelland et al 1997, Chappey et al 1998, Harada et
al 1998), in which the sialic acid levels were between 6 and 13 µg/mg protein.
Thus, there are large variations in the sialic acid ratios in studies by different
groups, and the results of this study are not the only ones that deviate from
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the majority of reports. The variability is not a question of methodology,
because the two methods employed in the earlier studies and the present
one give similar and reliable results as already discussed. Therefore, the
large differences in the sialic acid levels can not be explained, but with a
similar range in all the sections of the present study the measurements used
in them can be considered reliable.
The sialic acid content of LDL is expressed as ratio to the concentration of
apo B in LDL because of the high dependence of its concentration on that of
apo B, as already pointed out in the Methods chapter, and this having been
the praxis in all previous studies. In the present study, the concentration of
apo B was measured with an immunoturbidometric method (Riepponen et al
1987), while in most other studies the total protein of LDL has been
measured with the Lowry method (Lowry et al 1951). Apo B is the only
protein in LDL, and its concentration is very close to the total protein
concentration in LDL. The reproducibility of results with the apo B analysis
method is good, and the levels are closely similar to those obtained with the
Lowry method (apo B 35.1±1.6 mg/dl and total protein 38.7±1.7 mg/dl in
dense LDL, n=90, r=0.967). Thus, variability in protein measurements cannot
explain the differences in the sialic acid to apo B ratios observed in different
studies.
6.4 Lipoproteins and sialic acids
Negative associations between serum and lipoprotein lipid levels and LDL
sialic acid ratio have been described also earlier (La Belle and Krauss 1990,
Chappey et al 1995). In the present study, serum total and LDL cholesterol
levels had negative correlations with the sialic acid ratio of total LDL in the
large population of Study III. This indicates that high LDL cholesterol level is
associated with low LDL sialic acid ratio, both presumably accelerating
atherogenesis. However, in the smaller patient groups of Studies I, II and IV,
the negative associations between serum or LDL cholesterol concentrations
and LDL sialic acid ratios were not significant, similarly to two other studies
(Chappey et al 1995, Millar et al 1999), while La Belle and Krauss (1990) also
found a weak but significant negative association between the cholesterol
concentration and the sialic acid ratio of LDL. This can simply be due to the
connection not being strong enough to be seen in all populations.
Serum triglyceride levels have been inversely associated with LDL sialic acid
ratio (La Belle and Krauss 1990, Chappey et al 1995). In the present study,
the sialic acid ratio of total LDL had no association with serum triglyceride
levels, but in Study III it was negatively related with the triglyceride
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concentration of LDL. Furthermore, a clear negative association was seen for
dense and very dense LDL sialic acid ratios and serum triglyceride levels in
Studies II and III, and only for very dense LDL sialic acid ratio in Study IV. In
Study II, the subjects were divided into groups according to their serum
triglyceride level, and in the IIb hyperlipidemics high triglyceride levels were
associated with low sialic acid ratios in dense and very dense LDL, but not in
total LDL. Consequently, an inverse association seems to exist between
serum triglyceride levels and the sialic acid ratios of the denser LDL
subfractions.
High concentrations of apo B in serum and LDL are considered a remarkable
risk factor for CAD (Sniderman et al 1980). The sialic acid ratios of total and
dense LDL had strong negative associations with serum and LDL apo B
levels in Study III. However, in the smaller populations of Studies II and IV,
the relation with serum apo B level was significant only for very dense, and in
Study II, also for dense LDL sialic acid ratio. Again, the significant findings in
the large population suggest that there is a correlation that is not seen in
smaller populations. Overall, these associations of LDL sialic acid ratios with
serum and LDL lipid and apo B levels indicate that atherogenic lipid profiles,
specifically high cholesterol, triglyceride and apo B concentrations in LDL, are
connected with low LDL sialic acid ratios, especially in the dense and very
dense subfractions. On the contrary, no association between LDL sialic acid
ratios and HDL cholesterol level was seen in any of the studies.
The sialic acid ratios of the light, dense and very dense LDL subfractions
were in general negatively associated with the respective cholesterol,
triglyceride, phospholipid and apo B concentrations, the inverse association
being strongest for apo B concentrations. The correlations were significant in
dense LDL for all the lipid and apo B levels in every study section, and for
light and very dense LDL in almost all of them. As each LDL particle contains
one apo B molecule, the concentration of apo B reflects the number of LDL
particles. Thus, the inverse correlation between apo B concentration and
sialic acid ratio suggests that when the number of LDL particles is high, their
sialic acid content is low. In addition, the sialic acid ratios were positively
associated with the lipid to apo B ratios of total LDL and its subfractions,
which reflect the size of LDL particles. These observations together suggest
that low LDL sialic acid content is associated with a large number of relatively
small LDL particles, generally known to be atherogenic, and are also in
concordance with an earlier finding that subjects with small dense LDL have
a lower LDL sialic acid content (La Belle and Krauss 1990).
The ratio of sialic acid to protein was negatively associated with the density of
lipoproteins so that the ratio lowered from VLDL and IDL to LDL. Similar
decreases were described in three recent studies (Anber et al 1997, Harada
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et al 1998, Millar et al 1999). There is a number of possible explanations for
this loss of sialic acid from lipoproteins when density increases. First,
apolipoproteins other than apo B are lost during the conversion of VLDL into
IDL and further into LDL; second, the removal of sialic acid -rich apo B
-containg lipoproteins could be enhanced, and third, apo B could be
desialylated by a neuraminidase during this conversion into denser particles
owing to longer residence time in the circulation. The recently reported finding
that in plasma, LDL apo B is always partially desialylated (Bartlett and
Stanley 1998) suggests that desialylation of apo B does take place in plasma
and can contribute to the observed decrease in lipoprotein sialic acid ratio
with increasing density. On the other hand, LDL is richer in gangliosides than
VLDL (Senn et al 1989), and as the amount of sialic acid in the glycolipid part
of lipoproteins is thus higher in LDL than VLDL, the decrease in the sialic acid
content of the lipoproteins with delipidation indeed seems to ensue from a
loss of sialic acid from the glycoprotein, that is, apo B.
HDL was found to have a lower sialic acid ratio than any of the apo B
-containg lipoproteins, in concordance with a previous study (Harada et al
1998). This is undoubtedly due to the major apolipoproteins in HDL, apo A-I
and A-II, not being glycoproteins, the small amount of sialic acid thus residing
in the glycolipids of HDL and in some tightly bound glycoproteins like LCAT,
PLTP and CETP.
The sialic acid ratios have been reported to diminish also by increasing
density of LDL particles (La Belle and Krauss 1990, Millar et al 1999), in
continuation of the diminution in sialic acid ratio from triglyceride-rich apo B
-containing lipoproteins to LDL. Results from the present study partly support
previous findings, but are not totally concordant. In Study II, the sialic acid
ratio fell significantly from light to dense LDL only in the IIb but not in the IIa
group; however, the decrease was significant when both groups were
combined (53.2±2.2 to 42.1±2.2 µg/mg, P=0.002). In Study IV, the ratio
decreased clearly from light to dense LDL both at baseline and during the
statin treatment (P<0.01 for both). On the contrary, in Study I the sialic acid
ratios of the diabetic patients were similar in light and dense LDL, and in the
non-diabetic group, there was a non-significant decrease from light to dense
subfraction (P=0.09). In Study III, no significant decrease was seen either for
all the patients together or for CAD+ and CAD- subjects separately. However,
the positive associations of LDL sialic acid ratios with lipid to apo B ratios
suggest that when the sialic acid ratios are low, the particles are lipid-
depleted and thus denser and smaller in size. In summary, at least a
tendency towards decreasing sialic acid ratios with increasing particle density
was seen in most of the present study populations, and desialylation of LDL
apo B possibly contributes to this loss of sialic acid, supported by the multiple
findings of desialylated LDL in human plasma (Orekhov et al 1992, Tertov et
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al 1992a, Tertov et al 1992b, Sobenin et al 1993, Tertov et al 1993, Bartlett
and Stanley 1998).
In all the study sections and patient groups, the sialic acid ratio was clearly
highest in very dense LDL. This is most presumably due to the presence of
Lp(a), which is highly sialylated (Ehnholm et al 1972) and overlaps with the
density range of LDL. Separation of dense and very dense LDL was
performed to minimize the amount of Lp(a) in the dense subfraction and
apparently this succeeded, because the dense LDL subfraction, having a
remarkably lower sialic acid ratio, probably did not contain significant
amounts of Lp(a). Furthermore, separate measurements showed that less
than 30% of the subjects, all of whom had relatively high Lp(a) concentrations
in serum, had detectable amounts of Lp(a) in dense LDL, and in these
subjects its mean concentration in dense LDL was 16.6±2.9 U/l or 4.7% of
serum total Lp(a). Similarly, very dense LDL contained 8.3% of serum Lp(a).
6.5 LDL sialic acid content in different conditions
6.5.1 Type 2 diabetes mellitus
The sialic acid ratio of total LDL and its three subfractions was higher in DM
subjects than in the controls in Study I. The few DM patients in Studies II and
IV (8 and 5, respectively) did not differ significantly from the non-DM subjects,
but in both studies there was a non-significant tendency towards higher sialic
acid ratios in the DM subjects. These results are contradictory to earlier
observations by Tertov et al (1992a) and Sobenin et al (1993), who found
lower content of sialic acid in the LDL of DM patients compared with
normoglycemic controls. In addition, other studies have reported no
differences in LDL sialic acid ratio in normolipidemic subjects with or without
DM (Maruhama et al 1983, Ruelland et al 1997). The reason for the very high
sialic acid levels in the diabetic subjects of the present study might be in the
catabolism of LDL, which also differed from that of the non-DM subjects. Both
in Studies I and II the FCR for LDL apo B, and especially the FCR for dense
LDL apo B, was significantly higher in the DM subjects compared with
normoglycemic controls. This is opposite to what was expected, because the
FCR for LDL apo B has been reported to be decreased in DM (Howard et al
1987). Thus, the higher sialic acid ratio in LDL was associated with an
accelerated removal of LDL from the circulation in DM. On the other hand,
hypertriglyceridemia is often related with enhanced clearance of LDL (Vega
and Grundy 1989). The diabetic subjects in Study I had higher serum
triglyceride levels than the non-DM controls, which could explain their faster
LDL catabolism. The FCR for LDL apo B also had a positive correlation with
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serum triglyceride levels, so that both high LDL sialic acid ratio and high
serum triglyceride levels were connected with increased catabolism of LDL
apo B in DM.
6.5.2 Type IIa and IIb hyperlipidemia
Even though the study population was selected according to their lipid profile
and matched for age, sex and BMI, the composition of lipoproteins, especially
of LDL, was similar in type IIb to that presented for familial combined
hyperlipidemia (Kane and Havel 1995). As compared with IIa, in IIb
hyperlipidemia light LDL particles were lipid-depleted and fewer. The
composition of dense particles was similar in the two groups while in IIb the
numbers of both dense and very dense LDL particles were higher, and very
dense particles were poor in triglycerides and phospholipids. Thus, in IIb
subjects both the number and the production rate of dense LDL particles
were elevated.
The sialic acid ratios of dense and very dense LDL subfractions were lower in
IIb than IIa hyperlipidemia, in accordance with the negative correlation of the
sialic acid ratios of dense and very dense LDL with serum triglyceride levels.
In addition, LDL sialic acid ratio was low both in IIa and IIb hyperlipidemia
compared with a healthy female population. Both type IIa and IIb
hyperlipidemic subjects have an increased risk of CAD. In IIb hyperlipidemia,
elevated triglyceride levels are often associated with high concentrations of
dense LDL and low HDL cholesterol levels, this lipid profile being especially
atherogenic (Grundy 1995a). This was the case also in the IIb hyperlipidemic
subjects of the present study with high concentrations of dense LDL and non-
significantly lower HDL cholesterol levels compared with IIa subjects. It can
be assumed that the risk of developing CAD is even higher for IIb than IIa
subjects, and the lower sialic acid content in the atherogenic dense LDL
subfraction of IIb subjects could contribute to their increased risk.
6.5.3 Coronary artery disease
Low sialic acid content has been found in LDL of CAD patients in many
(Orekhov et al 1989, Orekhov et al 1991b, Tertov et al 1992a, Tertov et al
1992b, Ruelland et al 1993, Millar et al 1999) but not in all studies (Chappey
et al 1998). It has been suggested that desialylation is an atherogenic
modification of LDL taking place in the circulation, since sialic acid -poor LDL
has been found in blood, especially in that of CAD patients (Tertov et al
1992b). LDL with a low sialic acid content causes lipid deposition into cells
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(Filipovic et al 1979, Orekhov et al 1992) and binds to arterial proteoglycans
(Camejo et al 1985), which both phenomena are characteristic to
atheromatous lesions. Desialylized LDL can be considered as a minimally-
modified LDL that avidly internalizes in macrophage-foam cells. Thus, sialic
acid -poor LDL could be one relevant factor leading to the development of
CAD.
In the large patient groups of Study III, CAD+ patients had significantly lower
sialic acid ratios in total, dense and very dense LDL than CAD- subjects. This
gives further support to the theory that the sialic acid content of LDL might
affect its atherogenicity and thus predispose to the development of CAD.
However, at low levels of total and dense LDL sialic acid ratio (in Q1), CAD+
and CAD- subjects had similar mean sialic acid ratios, while at higher values
(Q2-Q4) CAD+ patients had lower mean sialic acid ratios than CAD- subjects.
This implies that the generally lower LDL sialic acid ratios in CAD+ than CAD-
subjects may not be seen in populations with low LDL sialic acid ratios. This
could partially explain the inconsistencies of previous studies in finding
differences in LDL sialic acid ratio between CAD+ and CAD- subjects.
Furthermore, LDL cholesterol level was inversely associated with LDL sialic
acid ratio and was higher in CAD+ than CAD- subjects. Thus, in stepwise
logistic regression analysis only the concentration of cholesterol in LDL, and
not its sialic acid ratio, was associated with the presence of CAD, which
indicates that LDL cholesterol concentration is more strongly associated with
CAD than is its sialic acid ratio.
However, in the other sections of the present study no clear association
between low sialic acid ratio and CAD was observed, but this can be
explained for instance by the following factors. The diabetic subjects, known
to have a very high CAD risk (Kannel and McGee 1979), had high LDL sialic
acid levels in Study I, and since the difference in LDL sialic acid ratio seems
to be strongest at high levels of sialic acid ratios, the diabetics should exhibit
marked differences between CAD+ and CAD- subjects. However, diabetic
CAD+ and CAD- subjects had equally high sialic acid ratios, and thus they
seem not to be comparable with non-diabetics. In the 10 normoglycemic
subjects in Study I, the sialic acid ratio did not differ significantly between
CAD+ and CAD- subjects in total LDL or its subfractions, but there was a
tendency towards lower sialic acid ratios in dense LDL of CAD+ subjects. In
Study II, the sialic acid ratios of total and dense LDL were very similar
between CAD+ and CAD- subjects, but this could be due to 8 out of the 10
CAD- subjects belonging to the IIb hyperlipidemia group and thus having a
high serum triglyceride level which was associated with a low LDL sialic acid
ratio. In Study IV, only 4 subjects did not have CAD, and their small number
does not allow to draw conclusions about the lack of differences in LDL sialic
acid ratio between CAD- and CAD+ subjects.
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Considering these confounding factors in the other sections of the present
study on this aspect, and the association being evident in Study III with the
largest number of patients, it can be deduced that non-diabetic CAD patients
have in general lower LDL sialic acid ratios than comparable subjects without
CAD. On the other hand, since to this day there are no follow-up studies on
the matter, it can not be excluded that subjects with a high LDL sialic acid
ratio could have an elevated rate of fatal AMIs, those with low values having
non-fatal AMIs; this would lead to surviving CAD patients having low LDL
sialic acid content compared with the general population. In the future, follow-
up studies will be crucial in the evaluation of this aspect.
In the combined IIa and IIb group in Study II, the sialic acid ratio was higher in
very dense LDL of CAD+ than CAD- subjects, while no differences were
detected in total LDL or in the other subfractions. This is probably related to a
higher level of Lp(a), known to be associated with CAD in many populations
(Genest et al 1991, Sandholzer et al 1992, Kario et al 1994, Bostom et al
1996). If total LDL or its light and dense subfractions were contaminated with
significant amounts of Lp(a), it probably would raise their sialic acid content.
Accordingly, it could be assumed that CAD+ patients would have a higher
LDL sialic acid ratio. However, even though CAD+ patients tended to have a
higher mean Lp(a) level in Studies II and III, they had generally lower LDL
sialic acid ratios than CAD- subjects. In addition, there was no correlation
between LDL sialic acid ratio and serum concentration of Lp(a) in the present
study, consistently with previous results (Chappey et al 1995). Moreover,
subjects with serum Lp(a) levels in the low or high end of the range had sialic
acid ratios in LDL and all its subfractions similar to those of all the subjects
together. These findings strongly suggest that the possible contamination of
LDL with Lp(a), except in the case of the very dense subfraction, was so
small that it can be considered insignificant. Furthermore, it can be presumed
that the fractions were equally contaminated with Lp(a) in CAD+ and CAD-
subjects, and in the case of a real contamination, the difference in the sialic
acid ratio between CAD+ and CAD- subjects would be even more marked in
pure LDL.
6.6 LDL sialic acid content and lipoprotein metabolism
6.6.1 LDL catabolism
Multiple types of scavenger receptors with the ability to mediate uptake and
degradation of modified lipoproteins have been found in atherosclerotic
lesions (Ylä-Herttuala 1996, Greaves et al 1998), while cells of these lesions
seem not to express LDL receptors (Ylä-Herttuala et al 1991, Luoma et al
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1994). The expression of scavenger receptors is induced by modified
lipoproteins, and cholesterol uptake by these receptors is not subject to
down-regulation thus allowing extensive intracellular cholesterol accumulation
(Greaves et al 1998). Sialic acid -poor LDL is capable of binding, besides to
the LDL receptor, to both an asialoglycoprotein receptor (Windler et al 1991)
and a galactose-specific lectin receptor (Grewal et al 1996). Both of these
receptors could act as scavenger receptors, and so a large part of
desialylized LDL could be cleared from the circulation through this
unregulated scavenger pathway, leading to the formation of foam cells.
Accordingly, the catabolism of sialic acid -poor LDL by the LDL receptor
would be slower than that of sialic acid -rich LDL. This hypothetical
mechanism is depicted in Figure 14. Earlier studies have reported increased
removal from the circulation for desialylated LDL, but the receptor pathway
used by desialylated LDL was not specified (Hendrix et al 1975, Malmendier
et al 1980).
Figure 14. Hypothetical scheme of the receptor interaction of sialylated LDL on the left and
desialylated LDL on the right.
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In Study I, a positive correlation between the sialic acid ratio of dense LDL
and the FCR for dense LDL apo B was seen, while the correlation between
these parameters in total LDL did not quite reach significance. The subjects
in this study were mainly diabetics with high LDL sialic acid ratios and high
FCRs for total and dense LDL. However, in the mostly non-diabetic subjects
of the other study sections no clear association came out. In Study II with 8
out of 43 subjects being diabetic, a significant positive correlation was
established between the FCR for total LDL apo B and the sialic acid ratio of
light but not that of total or dense LDL. Due to the small number of subjects in
the kinetic analyses of Study IV no conclusion can be drawn from the lack of
correlations between LDL sialic acid and metabolic parameters. In the
normoglycemic population in Study III, the FCRs for total and dense LDL apo
B were not significantly associated with their sialic acid ratios, although there
was a tendency towards a positive correlation between total LDL sialic acid
ratio and the FCR for LDL apo B (r=0.241, P=0.08). Interestingly, however, in
stepwise regression analysis the FCR for LDL apo B entered the model
explaining the variability of LDL sialic acid ratio along with the TR for LDL apo
B when the effect of the latter was removed. This suggests that both the
production and the catabolism of LDL are connected to some extent with its
sialic acid content. Globally, these data indicate that the sialic acid content of
LDL may have a weak positive correlation with its catabolism, the association
being stronger in diabetic subjects.
6.6.2 LDL production
The TR for dense LDL apo B was higher in IIb than IIa hyperlipidemia, and
had a strong positive correlation with serum triglyceride levels, implying that
in the presence of high triglyceride levels, the production of dense LDL
particles increases. This is supported by the fact that in FCHL (Kissebah et al
1984, Teng et al 1986, Venkatesan et al 1993) and in hypertriglyceridemia
(Vega et al 1985, Vega and Grundy 1989, Vega and Grundy 1998), there is
an enhanced production of apo B from the liver, and production rates for
VLDL and LDL are high. Thus, also more dense LDL particles are likely to be
formed. The TR for dense LDL apo B was also strongly correlated with the
esterification percentage of total LDL cholesterol in the IIa and IIb
hyperlipidemia subjects, which indicates that the more LDL and specifically
dense LDL is produced, the greater part of its cholesterol content is
esterified. Cholesterol esterification and ester transfer rates have been
reported to be higher in subjects with hypertriglyceridemia or combined
hyperlipidemia than in hypercholesterolemic or normolipidemic subjects
(Kudchodkar and Sodhi 1976, Murakami et al 1995), and to be positively
correlated with serum triglyceride level (Murakami et al 1995). This is in
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concordance with the finding of the present study that in
hypercholesterolemic subjects a high serum triglyceride level is associated
with a high esterification percentage in LDL.
The sialic acid ratios of both dense and very dense LDL manifested
significant negative correlations with the TR for dense LDL apo B in Studies II
and III. As in the case of LDL catabolism, the small number of participants in
the kinetic part of Study IV probably explains the fact that the association did
not reach significance in these subjects. In the large patient group in Study III,
also the sialic acid ratio of total LDL was inversely related with the TR for
dense LDL apo B, and the sialic acid ratios of total, dense and very dense
LDL were similarly connected with the TR for total LDL apo B; the negative
association between the production and the sialic acid ratio of LDL was even
stronger for dense LDL. This association of elevated production of LDL with a
low sialic acid ratio could be due to more sialic acid -poor than sialic acid -rich
VLDL, IDL and light LDL being converted into LDL and dense LDL, and/or to
sialic acid -rich lipoproteins being cleared more avidly from the circulation
before conversion into dense LDL. High production rate of LDL apo B could
also be linked with high neuraminidase activity causing accelerated
desialylation of LDL in the circulation. All of these mechanisms would lead to
a lower sialic acid ratio in total and especially in dense LDL. Thus, it would
seem that when the sialic acid ratio of lipoproteins is low, their catabolism is
slow leading to high production of dense LDL with a low sialic acid ratio. The
association of high production, slow catabolism, and large numbers of small
LDL particles with low LDL sialic acid ratio is presented in Figure 15. Slow
lipoprotein catabolism also leads to a long residence time, allowing
desialylation of LDL to occur in the circulation, and could lead to a bigger
proportion of LDL being cleared through the scavenger pathway and
eventually to an increase in the cholesterol content of macrophages in the
intimal layer of endothelium.
As the CAD patients in Study III had low LDL sialic acid ratios, and these
ratios were negatively associated with the TRs for total and dense LDL apo
B, they also had accelerated production of total and dense LDL apo B, in
concordance with findings in one previous study (Kesäniemi and Grundy
1983). It can thus be suggested that low sialic acid ratios in LDL and
especially in its dense subfraction associated with high TRs for total and
dense LDL apo B are atherogenic. Specifically, the higher production and
similar clearance of LDL apo B in CAD+ than CAD- subjects indicate longer
residence time in the circulation for LDL in CAD, and could allow more time
for desialylation of LDL. The mechanism of this desialylation is not known,
but neuraminidase is an enzyme having the ability to remove sialic acid
residues from carbohydrate chains, and its concentration in serum has been
found to be higher in CAD+ than CAD- subjects (Sonmez et al 1998).
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Figure 15. Schematic presentation of the metabolism of LDL and the size and concentration of
LDL particles in the case of high and low sialic acid to apo B ratio.
6.7 LDL sialic acid content and cholesterol metabolism
Serum ratios of the cholesterol precursor sterols ∆8-lathosterol, desmosterol
and lathosterol to cholesterol reflect cholesterol synthesis, while the ratios of
the plant sterols campesterol and sitosterol and the ratio of cholestanol reflect
cholesterol absorption (Miettinen et al 1990). The correlations of dense LDL
sialic acid ratio with serum non-cholesterol sterol ratios in the present study
indicate that a low sialic acid ratio in dense LDL was associated with high
synthesis and low absorption of cholesterol, and these were all connected
with a high TR for dense LDL apo B. A positive correlation between
cholesterol synthesis and TR for LDL apo B has also been observed earlier in
elderly men (Gylling et al 1994), but in middle-aged men no such correlation
was found, and contrary to the results now obtained, a positive correlation
between cholesterol absorption and TR for LDL apo B has been reported
(Miettinen et al 1992, Gylling et al 1994). However, recent studies with stable
isotopes have demonstrated a positive correlation between cholesterol
synthesis and hepatic production of VLDL apo B (Watts et al 1995c, Riches
et al 1997), and since in hypercholesterolemia both TRs for VLDL apo B and
LDL apo B are elevated (Teng et al 1986), also more dense LDL apo B is
presumably formed. This is in accordance with the present results which
suggest that the more cholesterol is synthesized, the more dense LDL is
produced, and the lower is its sialic acid ratio.
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No consistent differences in cholesterol metabolism have been reported
between CAD+ and CAD- subjects previously, but low cholesterol synthesis
rate was found to predispose to CAD in a study with FH patients (Miettinen
and Gylling 1988). This is in concordance with the finding of this study that at
high dense LDL sialic acid ratios, CAD+ subjects had lower lathosterol ratios
than CAD- subjects. The reason for this not being seen at lower sialic acid
ratios may be due to all the subjects with low sialic acid ratios having high TR
for dense LDL apo B, which in turn was associated with high lathosterol
ratios, and thus subjects with low LDL sialic acid ratios had high lathosterol
ratios independently of CAD status.
6.8 The effect of statin treatment on LDL sialic acid content
The change in the sialic acid ratios of total LDL and all its subfractions was
approximately similar in the groups treated with different statins, i.e.
cerivastatin (n=10), fluvastatin (n=9) and simvastatin (n=7). The cholesterol
concentrations of light and dense LDL subfractions at baseline were
negatively correlated with the respective baseline sialic acid ratios so that
when the cholesterol contents were decreased by statins, the sialic acid
ratios increased. Further, the more marked the decrease in cholesterol or apo
B concentration of dense LDL was, the greater was the increase in its sialic
acid ratio. Thus, since the strongest lipid lowering of LDL subfractions was
found in the most hypercholesterolemic subjects, it could be assumed that
these patients also had the biggest rise in sialic acid ratios. However, basal
lipid levels were not correlated with the change observed in the sialic acid
ratios.
Considering that desialylated LDL is supposed to be atherogenic, the new
finding that LDL sialic acid ratio rises during statin treatment could contribute
to the well-known observation that statin treatment is associated with a
regression of atherosclerosis. The decrease in dense LDL lipid and apo B
concentrations was related to the basal sialic acid ratio of dense LDL so that
a low sialic acid ratio at baseline predicted effective lowering of lipid and apo
B concentrations.
In a recent study by Orekhov et al (1997), the sialic acid content of LDL
increased in patients treated with amlodipine alone or with the combination of
amlodipine and lovastatin. The augmentation was seen more rapidly with the
combination treatment than with amlodipine alone, but after a treatment of
four weeks, the final level of sialic acid was the same whether or not
lovastatin was used. In contrast to these findings, results of the present study
imply that statin treatment alone causes a rise in LDL sialic acid ratio. Millar et
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al (1999) reported that ciprofibrate treatment reduced the sialic acid ratio of
lipoproteins, and although the sialic acid content was inversely associated
with the formation of atherogenic lipoprotein-proteoglycan complexes, the
formation of these complexes diminished during ciprofibrate treatment.
LDL sialic acid ratio rose in most but not in all subjects during the statin
treatment. The 5 subjects with a decreasing sialic acid ratio had a higher LDL
sialic acid ratio at baseline than the other subjects, but otherwise they had
identical clinical characteristics, baseline lipid and apo B concentrations and
LDL kinetic parameters, and the changes in these parameters during statin
treatment were comparable to those in patients with increasing LDL sialic
acid content. Because of the good reproducibility of sialic acid measurements
discussed earlier, the decreasing sialic acid ratios in some subjects can not
either be explained by error in the measurement. Consequently, it is difficult
to determine why their LDL sialic acid content responded differently.
As the lipid contents of lipoproteins fell during the statin treatment, their
metabolism was also affected. The FCRs for total and dense LDL apo B
increased, implying an accelerated catabolism. Furthermore, there was a
decrease in the TR for dense LDL apo B, reflecting a diminished production
of this subfraction, while the TR for total LDL apo B was not affected. This
suggests that statin treatment reduced the conversion of light LDL into the
more atherogenic dense subfraction, which has also been associated with a
lower sialic acid content (La Belle and Krauss 1990). However, there was no
connection between baseline sialic acid ratios and the changes in LDL
metabolic variables, but it should be noted that the number of subjects in the
kinetic study was limited.
The observed increases in LDL sialic acid ratio and LDL catabolic rate are in
concordance with the finding in Study I that high LDL sialic acid ratio is
associated with high FCR for LDL apo B, especially in diabetics. It is not
known which of these changes causes the other. Statin treatment augments
LDL catabolism by upregulating the activity of LDL receptors (Kovanen et al
1981, Reihner et al 1990), and TR for dense LDL apo B is apparently
decreased because of effective removal of lipoproteins of lower density. So, it
could be assumed that when the sialic acid content of LDL is high, its
catabolism by the LDL receptor accelerates, which also leads to lower
production of dense LDL. On the other hand, high LDL catabolic rate could
lead to a higher sialic acid content by leaving less time for desialylation of
LDL in the circulation. Both of these mechanisms can link high LDL sialic acid
ratio to enhanced catabolism of LDL and to low production of dense LDL.
Further confirmation to this would be given by investigating FH subjects, who
have a slow LDL catabolism and therefore presumably a low LDL sialic acid
ratio.
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7 SUMMARY AND CONCLUSIONS
The sialic acid content of lipoproteins has been suggested to affect
lipoprotein metabolism and the development of atherosclerosis. Therefore,
the sialic acid content of lipoproteins, especially that of LDL and its three
subfractions, and its relations to different lipid variables and lipoprotein and
cholesterol metabolism, as well as to DM, type IIa and IIb hyperlipidemias,
and CAD were investigated. Furthermore, the effect of statin treatment on
LDL sialic acid content was studied.
To study these aspects, subjects were examined as follows: 20 type 2 DM
subjects and 10 non-diabetic controls (Study I), 22 type IIa and 21 type IIb
hyperlipidemic subjects (Study II), 56 CAD and 42 non-CAD subjects (Study
III), and 26 hypercholesterolemic subjects before and during statin treatment
(Study IV). Lipoproteins were separated by ultracentrifugation, and sialic acid
contents were measured with the resorcinol method. The metabolism of
lipoproteins was investigated with radioactive iodine labeling, and that of
cholesterol by measuring non-cholesterol sterols from serum.
The sialic acid content of apo B -containing lipoproteins decreased with
increasing particle density from VLDL to LDL, and less consistently from light
to dense LDL. The sialic acid content of LDL was negatively correlated with
the concentrations of cholesterol, triglycerides, phospholipids, and apo B
especially in the dense LDL subfraction, and low sialic acid content was
associated with large amounts of relatively small LDL particles.
LDL sialic acid content had a weak positive correlation with the catabolism of
LDL apo B, the association being stronger in type 2 diabetes mellitus. The
production rate of LDL apo B was inversely related with LDL sialic acid
content, especially in dense LDL. Low sialic acid content in dense LDL was
also associated with high synthesis and low absorption of cholesterol, which
in turn were also related with high production rate of dense LDL apo B.
CAD patients had a lower sialic acid content in LDL, especially at high sialic
acid ratios, than non-CAD subjects. Type IIb hyperlipidemia was associated
with a low sialic acid content in dense and very dense LDL compared with
type IIa hyperlipidemia. Type 2 diabetic patients had higher sialic acid
contents in total LDL and its subfractions than non-diabetics, connected with
higher catabolism of LDL apo B. Age, sex, BMI, smoking and apo E
67
phenotype had no effect on LDL sialic acid ratio, neither had the use of beta-
blockers, thiazide diuretics or hormone replacement therapy.
Statin treatment increased the sialic acid ratio of LDL and its subfractions
proportionately to the decrease in cholesterol levels, and in dense LDL low
sialic acid content at baseline predicted effective lowering of cholesterol level
in the subfraction. Production of dense but not that of total LDL apo B
decreased during statin treatment, while catabolism of both total and dense
LDL apo B increased. The number of subjects in the kinetic study before and
during statin treatment was, however, so small that no associations were
found between the changes in kinetics and the sialic acid ratios of LDL.
In summary, a low sialic acid content in LDL and especially in its dense
subfraction was associated with CAD and with multiple variables related with
an increased risk of CAD, namely high serum and lipoprotein lipid levels, high
numbers of small LDL particles, and high production rate of dense LDL apo
B. In addition, statins increased the sialic acid content of LDL. Thus, low LDL
sialic acid content seems to be a risk factor of atherosclerosis and connects
with high lipoprotein lipid levels, and LDL sialic acid level is associated with
the metabolism of LDL apo B and cholesterol and is increased by statin
treatment proportionately to the decrease in lipid levels.
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